Xue Feng
Lu Han
Sijia Ma
Lanbo Zhao
Lei Wang
Kailu Zhang
Panyue Yin
Qiling Li- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
Cancerous tumors are severe diseases affecting human health that have a complicated etiology and pathogenesis. Microbes have been considered to be related to the development and progression of numerous tumors through various pathogenic mechanisms in recent studies. Bacteria, which have so far remained the most studied microbes worldwide, have four major possible special pathogenic mechanisms (modulation of inflammation, immunity, DNA damage, and metabolism) that are related to carcinogenesis. This review aims to macroscopically summarize and verify the relationships between microbes and tumoral in situ tissues from cancers of four major different systems (urinary, respiratory, digestive, and reproductive); the abovementioned four microbial pathogenic mechanisms, as well as some synergistic pathogenic mechanisms, are also discussed. Once the etiologic role of microbes and their precise pathogenic mechanisms in carcinogenesis are known, the early prevention, diagnosis, and treatment of cancers would progress significantly.
Introduction
Malignant tumors are the second leading cause of death for men and the third leading cause of death for women (Whitlock et al., 2015). The most common malignant tumors are related to lung cancer, colorectal cancer, breast cancer, and prostate cancer in high-income countries and stomach cancer, liver cancer, esophageal cancer, and cervical cancer in low-income countries. Tumors are complex entities formed by cancer cells and the tumor stroma via multiple and bidirectional interactions to establish dependencies essential for initiating tumorigenesis (Zanconato et al., 2019). The pathogenesis of malignant tumors is correlated with genetic inheritance, environment, dietary habits, radiation, and endocrine disorders (Torre et al., 2016). The factors related to cancer can be divided into two categories: exogenous and endogenous (Whitlock et al., 2015; Torre et al., 2016; Collaborators, U.S.B.o.D et al., 2018; D’Souza et al., 2019; Zanconato et al., 2019). Existing studies have proposed some possible relationships between tumors and microbes in different types of cancers (Nilsson et al., 2006; Guo et al., 2012; Kostic et al., 2012; Garrett, 2015; Mitsuhashi et al., 2015; Audirac-Chalifour et al., 2016; Lee Y. C. et al., 2016; Liu H. X. et al., 2018; Okushin et al., 2018; Aykut et al., 2019; Haruki et al., 2019). Cancers from different systems have unique observable microbes and modes of pathogenesis (Table 1). The cancer-related microbes, which play a potential vital role in carcinogenesis, might originate from exogenous infections or microbial dysbiosis. The latter means the composition of microbial community in dysbiotic individuals is significantly different from healthy individuals (Goodwin, 1988; Tan and Wong, 2011; Shanmughapriya et al., 2012; Cavarretta et al., 2017; Mao et al., 2018; Pushalkar et al., 2018; Brüssow, 2020).
Table 1 The main mentioned cancers in this review and the usually observable and representative microbes and pathogenesis.
The number of microbes living on and inside the human body is about the same as the human cells (3.8×1013 bacterial cells relative to 3.0×1013 human cells) (Ron et al., 2016). Different microbes colonize different habitats in the human body, which can not only affect human health by aiding in nutrition, combating pathogens, modulating the immune system, and so on, but also be related to the high-risk of tumorigenesis (Dethlefsen et al., 2007; Cong and Zhang, 2018; Whisner and Aktipis, 2019). Because of the high mortality associated with malignant tumors (Whitlock et al., 2015; Collaborators, U.S.B.o.D et al., 2018; D’Souza et al., 2019), a new direction in therapy for treating microbes is innovatively put forward. Although possible relationships have been stated in various separate systems and pathogenic pathways, there is little correlative literature that sums up different cancers in a macroscopic view. Systematic information on microbes in different cancers has been hard to find.
This review aims to macroscopically summarize and verify the relationships between microbes (mainly bacteria) and tumoral in situ tissues from urinary, respiratory, digestive, reproductive, and other systems and to discuss the four major microbial pathogenic mechanisms related to carcinogenesis (the modulation of inflammation, immunity, DNA damage, and metabolism), as well as some synergistic pathogenic mechanisms (Table 2). We hypothesized that the regular monitoring of microbial changes might play a supervisory and manageable role in the development of cancer. This would represent a new challenge and opportunity for cancer prevention and treatment.
Table 2 The main mentioned cancers and microbes in this review from different pathogenic mechanisms.
Relations Between Microbes in the In Situ Tissue and Tumors
Prostate Cancer
A chronic persistent bacterial infection has been hypothesized as a possible etiology of prostate cancer due to the signs of inflammation in most precancerous and cancerous tissues (Lax and Thomas, 2002; Z, 2002; Nelson et al., 2003; Feng et al., 2019). To discover the relationship between microbes and prostate cancer, Feng et al. used integrated metagenomics and metatranscriptomics approaches to analyze 65 Chinese radical prostatectomy tumoral specimens and the adjacent benign tissues. The results showed that there was no microbial difference between the two groups in terms of alpha-diversity. This phenomenon was different from the expected difference, which might occur due to the close proximity of the compared regions and to the field effect. It was unclear whether the difference in genera or species existed (Feng et al., 2019).
However, Cavarretta et al. used extensive ultradeep pyrosequencing to detect the microbes in different tissues, including tumor, peri-tumor (PT), and non-tumor (NT) tissues from 16 white Caucasian non-diabetic nonobese prostate cancer patients who had not reported a prior known sexually transmitted infection or a recent history of urinary tract infection. Differences in terms of the microbial environment existed among the different zones of the prostate, especially the transition zone versus the peripheral zone. The microbes belonging to the PT region were more similar to the tumor region with respect to the NT region. This opposite result might be related to the rigorous entry standard for patients without other infectious diseases (Cavarretta et al., 2017).
To reduce the impact of close proximity of the compared regions and the field effect thoroughly, Miyake et al. examined 45 prostate cancer patients who underwent robotic prostatectomy and 40 benign prostatic hyperplasia patients. The rate of Mycoplasma genitalium infection in the prostate cancer patients was higher than in the benign prostatic hyperplasia patients (Miyake et al., 2019). The above microbial differences between the tumoral lesions and the nonneoplastic tissues indicated that microbes might be novel biomarkers and/or therapeutic targets for prostate cancer. In addition to being affected by microbes, the extracellular environment in prostate cancer might also conversely promote the establishment of specific microbes. The dysbiosis of the urinary microbes has not been fully confirmed as a cause or an effect for cancer (Cavarretta et al., 2017).
Lung Cancer
The field of lung microbial studies is rapidly growing and has achieved provocative results regarding the relationship between lung microbes and cancer (Dickson et al., 2013; Goto, 2020; Sommariva et al., 2020; Xu et al., 2020). Because lung biopsy extraction from healthy people is unethical, some experiment data has been based on bronchoalveolar lavage, bronchoscopic brushing, or sputum samples, which have showed an abnormal increase in microbes in lung cancer (Hosgood et al., 2014; Perez-Losada et al., 2017; Tappenden et al., 2017). Laroumagne et al. showed that gram-negative bacteria, such as Haemophilus influenzae, Enterobacter spp. and Escherichia coli, colonized 39.8% of 216 lung cancer bronchoscopic samples (Laroumagne et al., 2011). Hosgood et al. discovered that Granulicatella, Abiotrophia, and Streptococcus were enriched in non-smoker lung cancer cases compared with healthy controls (Hosgood et al., 2014). Yan et al. compared the salivary samples of 20 lung cancer patients and 10 control subjects and discovered that Capnocytophaga, Selenomonas, and Veillonella were more abundant while Neisseria was less abundant in both squamous cell carcinoma and adenocarcinoma patients than controls. In addition, the combination of Capnocytophaga and Veillonella, two bacterial biomarkers, performed well in the prediction of squamous cell carcinoma and adenocarcinoma, which might be related to lung cancer screening (Yan et al., 2015). In a study with 10 sputum samples, Streptococcus viridans was more abundant in lung cancer patients than controls. Other sixteen bacterial species were found only in lung cancer patients, meanwhile 7 other species were revealed only in controls (Cameron et al., 2017). Lee et al. discovered that two phyla (Firmicutes and TM7) and two genera (Veillonella and Megasphaera) were relatively abundant in broncho alveolar lavage fluid of lung cancer patients (Lee S. H. et al., 2016).
However, samples from these alternative locations might contain contamination from the upper respiratory tract. The analysis of lung tissues has provided a more accurate assessment of microbes in lung cancer (Tappenden et al., 2017; Mao et al., 2018). H.-X. Liu et al. chose 24 patients with lung cancer, collecting cancerous sites and contralateral noncancerous sites as paired samples, and 18 healthy controls undergoing bronchoscopies. The microbial alpha diversity declined steadily from the healthy sites to the noncancerous sites to the cancerous sites. At the genus level, Streptococcus was more abundant in the cancer samples than in the controls, while Staphylococcus was more abundant in the controls (Liu H. X. et al., 2018). Yu et al. discovered that the alpha diversity in lung tumor tissues was lower than normal tissues, which was the same as the discovery by Jin J et al. (Yu et al., 2016; Jin et al., 2019). The phylum Proteobacteria (predominantly genera Acinetobacter and Acidovorax) showed a higher abundance and phylum Firmicutes (genus Streptococcus) and Bacteroides (genus Prevotella) exhibited a lower abundance in patients with lung cancer than emphysema (Liu Y. et al., 2018). In addition to nonmalignant and tumoral tissues, different types of lung cancer also showed a big difference in microbial content. Adenocarcinoma tumor tissues were found to have a significantly higher phylogenetic diversity, an increased relative abundance of Thermus and a decreased relative abundance of Ralstonia in comparison to squamous cell carcinoma (Yu et al., 2016). Acinetobacter, Propionibacterium, Phenylobacterium, Brevundimonas, and Staphylococcus were the major genera of adenocarcinoma, while Enterobacter, Serratia, Kluyvera, Morganella, Achromobacter, Capnocytophaga, and Klebsiella in squamous cell carcinoma. Legionella was found to be higher in patients with metastatic tumors (Yu et al., 2016; Gomes et al., 2019). Greathouse et al. detected that Acidovorax, Klebsiella, Rhodoferax, and Anaerococcus bacteria showed a significantly higher abundance in squamous cell carcinoma than in adenocarcinoma (Greathouse et al., 2018). The abovementioned differences between tumoral and noncancerous tissues and between different types of lung cancer, whether in samples of bronchoalveolar lavage, bronchoscopic brushing, sputum or lung tissues, have greatly advanced microbial studies of the development of lung cancer (Hosgood et al., 2014; Perez-Losada et al., 2017; Tappenden et al., 2017; Mao et al., 2018).
Pancreatic Cancer
To learn more about pancreatic cancer, some studies have pointed out the possible existing relationship between microbes and tumors (Siegel et al., 2018). The specific microbial identification might be helpful for the early detection and treatment of pancreatic cancer (Zhang et al., 2019b).
Ertz-Archambault et al. concluded that Helicobacter pylori (H. pylori), only for cag-A negative H. pylori strains but not cag-A positive, and Fusobacterium were possibly the major microbes affecting pancreatic cancer incidence (Ertz-Archambault et al., 2017). Mitsuhashi et al. observed 283 formalin-fixed, paraffin-embedded tissue specimens of pancreatic cancers. Fusobacterium was detected in 8.8% of the tumor tissues. The Fusobacterium species in the tumor was associated with a shorter survival in patients with pancreatic cancer (Mitsuhashi et al., 2015). However, Fan et al. supposed that Fusobacterium and Lepotrichia were protective and associated with a reduced risk of pancreatic cancer (Fan et al., 2018). The diverse results should also be drawn attention (Mitsuhashi et al., 2015; Fan et al., 2018). Nilsson et al. detected the DNA of enteric strains of Helicobacter that colonized the pancreas in 75% of the adenocarcinoma patients, 57% of the patients with neuroendocrine cancer, 38% of the patients with multiple endocrine neoplasia, 60% of the patients with chronic pancreatitis, but not in the control patients with benign disease or normal pancreas (Nilsson et al., 2006; Ertz-Archambault et al., 2017). Smruti Pushalkar et al. observed a greater presence and a larger abundance of bacteria in both mouse and human pancreatic ductal adenocarcinoma (PDA) tissues compared with normal pancreas tissues (Pushalkar et al., 2018). Berk Aykut et al. discovered that there were differences in the composition of fungi in tumoral samples and normal pancreatic samples. The Malassezia species was enriched in PDA tissues in both mice and humans. In addition, ablation of the microbes could prevent the progression of PDA and repopulation of the Malassezia species. The presence of H. pylori and Malassezia in pancreatic cancer was possibly due to passage of the intestinal flora through the pancreatic duct (Matsuda et al., 2009; Aykut et al., 2019).
Gastric Cancer
H. pylori is a type of diverse bacterium with several virulent strain variations. The presence of H. pylori is mainly responsible for gastric inflammation and ulceration and significantly increases the risk of gastric cancer. This phenomenon was discovered by Barry J. Marshall and J. Robin Warren, who were awarded the Nobel Prize in physiology for this discovery (Tan and Wong, 2011; Kalaf et al., 2013; Chen et al., 2014).
Uemura et al. chose 1,526 Japanese patients with duodenal ulcers, gastric ulcers, gastric hyperplasia, or non-ulcer dyspepsia who underwent endoscopy with biopsy at enrollment and then again at between 1 and 3 years after enrollment. After the follow-up period of 7 years, 36 gastric cancers (2.9%) were demonstrated in 1,246 patients with H. pylori infection and none in 280 patients without H. pylori infection. It appears that gastric cancer rarely occurs in the absence of H. pylori infection. Continuous H. pylori infection has been shown to lead to a high risk of gastric cancer (Luan et al., 2019). With the widespread recognition that H. pylori leads to gastric cancer, people have paid more attention to the eradication of H. pylori, and the use of quadruple drug therapy is common (Kim, 2019). Lee et al. conducted a meta-analysis to discover the effectiveness of treating H. pylori infection. Individuals who underwent an eradication of H. pylori demonstrated a lower incidence of gastric cancer than those who did not receive eradicative therapy. This result helped to confirm the therapeutic effectiveness of eradicating H. pylori (Lee Y. C. et al., 2016).
Colorectal Cancer
Because the nonuniform bacteria present in different regions and stages of colorectal cancer, bacteria might play a role in prediction of early versus invasive cancer (Zorron Cheng Tao Pu et al., 2019). In 1971, Moore et al. analyzed the human fecal floras to know whether bacterial species were directly associated with high risk of colon cancer. However, this project was discontinued due to the complexity of the human intestinal flora and the limitations of statistical and analytical methods (Finegold et al., 1974; Moore and Holdeman, 1974; Holdeman et al., 1976). Since then, microbes had been investigated and recognized as major environmental factors relevant to colorectal cancer all over the world. Moore et al. reported that 15 bacterial species were significantly associated with a high risk of colorectal cancer in 1995 (Moore and Moore, 1995). Iradj Sobhani et al. used pyrosequencing to detect the bacterial genes and reported on the bacterial differences between cancer tissues and normal tissues. Bacteroides and Prevotella revealed an elevated level in cancer compared to normal groups, while other microbes showed no obvious difference (Sobhani et al., 2011). Kostic et al. characterized the composition of the microbes in colorectal cancer using whole genome sequences from nine tumoral and normal pairs. Fusobacterium sequences were enriched in carcinomas, while the Bacteroidetes and Firmicutes phyla were depleted (Kostic et al., 2012). Castellarin et al. reported that the presence of Fusobacterium nucleatum DNA was 415 times greater in tumor tissues than adjacent normal tissues, which might be associated with colorectal cancer (Castellarin et al., 2012). However, in a replication study, Fusobacterium nucleatum was detected in only 25% of colorectal carcinomas, which had no significant difference between tumor and adjacent tissues. This conflicting results might due to the differences of the populations or the technical issues (Repass et al., 2016). The following replication study showed that the difference in Fusobacterium nucleatum expression between colorectal cancer and adjacent normal tissues was smaller than the original research, and this bacterium was not detected in most samples, which could not confirm the results previously published, either. It was waiting to be solved whether the method of qPCR and primer and probe sequences, similarities, and differences in patient characteristics (Klevorn and Teague, 2016), and influence of diet on the gut microbiota (Mehta et al., 2017) could affect the result of this study (Repass et al., 2018). Just as for tumoral and normal pairs, the early and invasive colorectal cancer had different composition of microbes. Oribacterium, Bacterioides, and Prevotella were enriched in early cancer. Meanwhile, Bacterioides, Oribacterium, and Fusobacterium were found more abundant in the invasive cancer samples. The relative abundance of Fusobacterium increased in invasive cancer samples compared with early cancer samples in this study (Kostic et al., 2012; Haruki et al., 2019). Escherichia coli (E.coli)and Bacteroides fragilis were frequent, persistent mucosal colonizers of the familial adenomatous polyposis (FAP) gastrointestinal tract (2018). Citrobacter rodentium infection has been shown to promote the development of colon tumors in a murine model (Tan and Wong, 2011). The Apc min/+mice (the mice model with adenomatous polyposis coli (APC) gene mutation) gavaged with feces from colorectal cancer patients had more intestinal tumors compared with healthy controls or the mice gavaged with phosphate-buffered saline (Li et al., 2019).
Cervical Cancer
The changeable factors altering the vaginal microenvironment, such as bacterial vaginosis (Guo et al., 2012) or sexually transmitted infections (Vriend et al., 2015), have been identified as cofactors in persistent human papillomavirus (HPV) infections (Clarke et al., 2012). The bacterial differences of diversity between cancerous and noncancerous tissues had been discovered. Tango et al. discovered that nine genera and 21 species were significantly more abundant in cervical cancer group compared to the controls (Tango et al., 2020). Audirac-Chalifour et al. selected 32 cases containing 20 non-cervical lesions (NCL: 10 HPV-negative; 10 HPV-positive), four squamous intraepithelial lesions (SILs: all HPV-positive), and eight cervical cancer lesions (CCL: all HPV-positive) to analyze the alpha-diversity and the β-diversity in each group. HPV-negative NCL showed a significant difference in the diversity of the bacteria with SIL and CCL. The CCL samples showed a higher diversity compared with the NCL-HPV negative samples. Sneathia spp., Megasphaera elsdenii, and Shuttleworhia satelles were most representative in SIL. The most abundant species in the cervix of women with SIL was Sneathia spp., which was less abundant in patients with cervical cancer, whereas the most abundant species was Fusobacterium spp. in CCL samples and L. crispatus and L. iners in samples with a normal cytology. (Audirac-Chalifour et al., 2016). Not only cervical microbes but also abnormal vaginal ones were associated with the development of cervical cancer (Guijon et al., 1992). The Chlamydia trachomatis were reported to be a possible co-factor for cervical cancer development (Lehtinen et al., 2011). So et al. exhibited that the diversity of vaginal microbes was higher in cervical cancer than normal women. The proportion of Lactobacillus species were decreased in cervical disease. The abundance of L. crispatus in vagina was significantly reduced in cervical cancer. The infections of Atopobium vaginae, Dialister invisus, Finegoldia magna, Gardnerella vaginalis, Prevotella buccalis, and P. timonensis were significantly associated with the high risk of high-grade squamous intraepithelial neoplasia and cervical cancer (So et al., 2020). The depletion of Lactobacillus spp. and overgrowth of diverse obligate and strict anaerobic bacteria were supposed to be relevant to an increased risk of HPV acquisition and decreased clearance of HPV (Watts et al., 2005; Gillet et al., 2011; Guo et al., 2012).
Ovarian Cancer
The miscellaneous different microbes in ovarian cancers and control samples indicate that they might affect the microenvironment of ovarian tissues. Shanmughapriya et al. discovered that Chlamydia were present in 70% of the ovarian cancer tissues compared with healthy controls (Shanmughapriya et al., 2012). Li et al. proposed that the composition of bacteria and archaea was significantly different between cancerous and noncancerous ovarian tissues in situ. Aquificae and Planctomycetes were found to be increased in cancerous tissues, while the Crenarchaeota were found to decreased when compared to noncancerous tissues at the phylum level. In cancerous tissues at the class level, Spartobacteria were found to be increased and Sphingobacteriia were found to be reduced. The phylum, class, order, family, genus and species level of bacteria were all found to be significantly different between cancerous and noncancerous tissues. At the species level, Gemmata obscuriglobus dominated the cancer group, followed by Halobacteroides halobius and Methyloprofundus sedimenti. Halobacteroides halobius dominated the control group, followed by Gemmata obscuriglobus and Methyloprofundus sedimenti. In genus level, the relative abundance of Paenibacillus, Haloferula, Subdivision, Zavarzinella, Photorhabdus, Volucribacter, Blastococcus, Mesotoga, Defluviitoga, and Dorea was significantly different between cancer and control groups. Particularly, the relative abundance of Anoxynatronum sibiricum might be associated with the stage of tumor (Li, 2020). Banerjee et al. used PathoChip, a very sensitive approach to detect human pathogenic microorganisms, to screen the microbes in 99 ovarian cancer samples and 20 matched (tissues adjacent to the tumor deemed to be noncancerous), as well as in 20 unmatched control samples. Proteobacteria and Firmicutes were found in the majority of all three samples, as well as Bacteroidetes, Actinobacteria, Chlamydiae, Fusobacteria, Spirochaetes, and Tenericutes at lower percentages. The composition of microbes were quite different among the ovarian cancer samples, matched samples and unmatched samples. The bacterial signatures detected in the cancer samples were significantly higher than the controls. Pediococcus signatures were detected with the highest hybridization signal in the ovarian cancer samples, closely followed by Burkholderia, Sphingomonas, Chryseobacterium, Enterococcus, Staphylococcus, Treponema, Francisella, and Shewanella signatures. For other microbes, signatures of Pneumocystis, Acremonium, Cladophialophora, Malassezia, and Microsporidia Pleistophora were detected in all ovarian cancer samples. Rhizomucor, Rhodotorula, Alternaria, and Geotrichum were shown in more than 95% of ovarian cancer samples. Brucella, Chlamydia and Mycoplasma were detected in 76%, 60%, and 74% of the ovarian cancer samples, respectively. The viral sequences were integrated widely into the genome of the tumor tissue, especially the high risk HPV16 and 18 along with other low risk HPVs. The integration of HPV genomic regions into the human genome had been considered as an important event in cancer development (Funda, 2007; Al-Shabanah et al., 2013; Kadhim et al., 2014). Merkel cell Polyomaviruses were significantly detected in the ovarian cancers but undetectable in the controls (Banerjee et al., 2017). Herpesviruses (Shanmughapriya et al., 2012; Pandya et al., 2014), and Retroviruses (McLaughlin-Drubin and Munger, 2008; Johal et al., 2010) had been detected in 50% and 16%, respectively, of ovarian cancers. The specific retroviral probes in the majority of cancers were Mammary Tumor Virus and Foamy Virus. The genomic integration of human herpesviruses -6a at the telomeric region could be a contributing factor to ovarian cancer (Banerjee et al., 2017). The abnormal microenvironment might influence the incidence and progression of ovarian cancer. However, it cannot be denied that the specific tumoral environment might also provide a specialized niche for the microbial colonization (Banerjee et al., 2017).
Other Cancers
In squamous cell carcinomas, such as head and neck squamous cell carcinomas and oropharyngeal squamous cell carcinoma (OSCC), a difference of the relative abundance and diversity in the microbes between tumoral and normal tissues is proposed to exist, which reveals the possible relationships between microbes and cancers in most parts of the human body (Hozumi et al., 1972; Wang et al., 2017; Wolf et al., 2017; Zhao et al., 2017). Wang et al. compared the relative abundance of individual taxa between tumoral and normal tissues in head and neck squamous cell carcinomas. For not only Actinomycetes themselves, but also the parent taxa of Actinomycete which could be up to the phylum level, their relative abundance was significantly relatively increased in low-stage patients compared with high-stage patients. Actinomycetes might play a protective role by secreting protease inhibitors that inhibit tumorigenesis (Hozumi et al., 1972). In contrast, the Parvimonas genus and its family Tissierellaceae were found to be increased in tumors relative to normal tissues. These differences were more pronounced in patients with a higher T stage (Wang et al., 2017).
Of the human oral microbes, there are probably 500 to 700 common oral species or phylotypes, which might impact the luminal system to lead to OSCC (Samaranayake and Matsubara, 2017; Wolf et al., 2017). The oral microbes showed a significant difference between cancer patients and healthy humans. Wolf et al. analyzed saliva samples from 11 patients with OSCC and 11 healthy controls by high-throughput sequencing of the 16S rRNA gene using the MiSeq platform. Signatures of Bacteroidetes (e.g. Prevotella), Proteobacteria (e.g. Haemophilus and Neisseria), and Firmicutes (e.g. Streptococcus and Veillonella ) were more abundant in the healthy controls, whereas signatures of Actinobacteria (e.g. Actinomyces), Firmicutes (e.g. Schwartzia and Selenomonas), and Spirochaetes (e.g. Treponema) were more abundant in the OSCC patients (Wolf et al., 2017). Zhao et al. observed 40 tumoral and matched normal control samples from the same individual with OSCC. Compared with the corresponding clinically normal control samples, the diversity of the bacterial community in the cancer samples was significantly increased. The lesion surface of OSCC showed a higher phylogenetic diversity. The bacterial taxa between the cancer and control samples showed the opposite relationships. This implies that the enormous changes of bacterial symbiotic relationships might be associated with the occurrence of OSCC (Zhao et al., 2017).
Different Mechanisms of Carcinogenesis
Inflammation
Inflammation can result in a series of pathological changes, such as cancer and fibrosis (Hanahan and Weinberg, 2000; Karin and Clevers, 2016). Soluble and cellular inflammatory mediators are responsible for tumor development and progression (Galdiero et al., 2017). Up to 10%–20% of all cancers could be attributed to infections (Grivennikov et al., 2010). The following results showed some cancers that were related to inflammation caused by microbes.
In recent studies, human microbes might influence the initiation and/or progression of prostate cancer through both direct and indirect interactions, such as infecting and inducing both symptomatic and asymptomatic inflammatory responses in the prostate (Yoon et al., 2012; Caini et al., 2014; Cavarretta et al., 2017).
The distribution of microbes in the lung has been shown to be affected by many factors, such as environment and geography (Ubags and Marsland, 2017). Pre-existing Mycobacterium tuberculosis might increase the risk of lung cancer (Ardies, 2003; Khoruts, 2018). The relationship between M. tuberculosis and lung cancer was proposed based on previous studies of chronic inflammation-associated carcinogenesis, showing increase in tumor necrosis factor and excessive and persistent local inflammation at sites of repair and fibrosis (Coussens and Werb, 2002; Ardies, 2003). Some cytokines might promote the survival of malignant cells as autocrine growth factors (Mantovani, 2001).
The animal and human studies showed that inflammation might have an impact on the development of colorectal cancer (de Visser et al., 2006; Kuraishy et al., 2011; Kux and Pitsouli, 2014; Karin and Clevers, 2016; Li et al., 2019). Microbes in colorectal cancer patients might destroy the intestinal barrier, leading to the subsequent induction of pro-inflammatory cytokines, such as the reactive oxygen species (ROS), which promoted regeneration and predisposed to tumorigenesis (Kuraishy et al., 2011; Kux and Pitsouli, 2014; Li et al., 2019). The blood cell infiltration was thought to be induced by intestinal inflammation and tumor-promoting inflammation in mammals possibly (de Visser et al., 2006). It was reported that the tissue regeneration caused by inflammation might play a role in inflammation-driven carcinogenesis. Inflammation due to microbial pathogens could interfere with signaling pathways to affect several cytokines and growth factors, such as IL-6, IL-2, and tumor necrosis factor, to control the process of regeneration in injured intestinal mucosa. The signaling pathways included mitogen-activated protein kinase–AP-1, IKK–NF-κB, Hippo–YAP, Notch, the Epidermal Growth Factor Receptor, Target-of-rapamycin/Vascular Endothelial Growth Factor Receptor, JAK/STAT, and Wnt/Wg signaling, and so on (Stavria and Yiorgos, 2013; Kux and Pitsouli, 2014). Inflammation and cancer might affect and promote each other. The cancer cells could also express inflammatory cytokines in turn to recruit immune cells to cause tumor-related inflammation (Kuraishy et al., 2011). Fusobacterium sequences were enriched in carcinomas (Kostic et al., 2012), which could bind to host epithelial Cadherin 1 through the adhesion of FadA and invade epithelial cells from through the E-cadherin/β-catenin signaling to induce inflammation and tumor cell growth in transformed cells (Rubinstein et al., 2013; Wong and Yu, 2019; Guo P. et al., 2020).
Immunity
Microbes might affect the immune status to promote the development and progression of several cancers, as described in a number of studies (Rooks and Garrett, 2016; Goodman and Gardner, 2018; Pushalkar et al., 2018). Different immune status can promote the tumor progression. Cancer and cancer-related disease can be affected by the immune status in turn. For example, the occurrence of tuberculosis in lung cancer patients might be accelerated after chemotherapy due to low immunity (Christopoulos et al., 2014; Khoruts, 2018; Pandey et al., 2019). A low immune status that means immunosuppression is one of the potential mechanisms of microbial carcinogenesis that allow the tumor to grow and infiltrate (Shalapour and Karin, 2019). The tumor-associated macrophages play a key role in inhibiting T cell recruitment and function, thus facilitating tumor immune escape (Quaranta and Schmid, 2019). Not only the low but also the wrong and excessive immune status could affect the incidence of cancer. Once the innate immunity is activated, the MHC class I and II and costimulatory molecules are upregulated, as well as numerous inflammatory chemokines and cytokines, then the adaptive immune cells are activated to amplify the initial inflammatory response (Monney et al., 2002; Steinman, 2012). Tumor-associated neutrophils could release ROS and neutrophil elastase to mediate cancer cell killing and promote metastasis (Galdiero et al., 2013). Tumor-associated macrophages could induce the wrong immune reaction to play a supportive role in cancer development and progression (Galdiero et al., 2013; Ruffell et al., 2014)
In PDA, it was demonstrated that microbes might activate selected toll-like receptors (TLR) in monocytic cells to generate a tolerogenic immune program. TLR2 and TLR5 ligation was demonstrated to induce innate and adaptive immune suppression, which promote PDA. Without the TLR signaling, the immune suppression by the macrophages would not occur. Therefore, the management of microbes to reduce immune suppression might be an attractive method for pancreatic cancer treatment (Pushalkar et al., 2018).
The importance of gut microbes in intestinal carcinogenesis in modulating the tumor immune microenvironment has been improved by several researches (Rooks and Garrett, 2016; Goodman and Gardner, 2018; Gopalakrishnan et al., 2018; Routy et al., 2018; Tilg et al., 2018). In MSI-high colorectal cancer, the abundant neoantigens due to a large number of transcoding mutations could lead to a strong immune response to the tumor (Ogino et al., 2009; Nosho et al., 2010; Rizvi et al., 2015; Chantziantoniou et al., 2017; McDermott et al., 2017). The microbes in ileum could transform the tolerogenic apoptosis of ileal intestinal epithelial cells into immunogenic cell demise, then elicit IL-1β-dependent follicular T helper responses (Roberti et al., 2020). As for the sustained survival of colorectal carcinoma (CRC) cells, Fusobacterium could exert an immunosuppressive effect in the cancer microenvironment (Saito et al., 2016; Thiele Orberg et al., 2016; Hussan et al., 2017; Park et al., 2017; Ye et al., 2017). IL17 immune cells and Bacteroides were found to have infiltrated the majority of the tumor samples and the lamina propria of homologous normal mucosa in cancer patients, while they were rarely or not detected in the mucosa of normal individuals. It was concluded that Bacteroides might change the immune microenvironment relative to the incidence of cancer (Sobhani et al., 2011). Jasemi et al. classified Bacteroides fragilis into three groups based on biofilm formation ability and toxin encoding gene presence and its flanking region. Enterotoxigenic Bacteroides fragilis strains with Bacteroides fragilis toxin gene was defined as pattern I, and non-toxigenic strains were defined as Pattern II and III. Pattern II was defined as strains without the pathogenicity island region and flanking region. Pattern III was defined as strains without the pathogenicity island and with flanking region. The abundance of patterns were different between CRC and normal tissues, which meant pattern I > III > II in normal tissue and pattern II > III > I in CRC tissue. The strains isolated from CRC tissue had higher biofilm forming ability than the strains isolated from normal tissue (Jasemi et al., 2020). Intestinal mucosal IL17A could not only protect the intestine from pathogens but also provide transition to promote CRC development. Chronic mucosal formation of IL17A produced by Th 17 cells might alter signaling pathways in colon epithelial cells or induce changes or mutations in DNA structure that facilitated the transformation of colon epithelial cells contributing to carcinogenesis (Hurtado et al., 2018).
H. pylori has been shown to play a possible role in hepatocellular carcinoma (HCC) because the H. pylori genes frequently has been detected in resected HCC specimens (Guo et al., 2012; Mitsuhashi et al., 2015; Lee Y. C. et al., 2016; Okushin et al., 2018; Haruki et al., 2019). Some in vitro studies using cancer cell lines discovered an indirect pathogenesis, possibly including immune changes, due to H. pylori in HCC (Zhang et al., 2005; Ito et al., 2008; Pekkala et al., 2019). HCC is usually accompanied by liver fibrosis in which the intrahepatic immune status and hemodynamics might be changed, leading to the inflow of H. pylori and escape from immunity in the liver. However, it was not confirmed whether H. pylori played a causative role in the development of HCC. In animal experiment, H. pylori infection did not promote the development of HCC in transgenic mice expressing HCV proteins (Ki et al., 2010; Garcia et al., 2013; Okushin et al., 2018). Therefore, a correlation between H. pylori infection and HCC was not strongly supported. Further experiment should be performed.
Microbes might produce immune substances to modulate the development of SIL and cervical cancer, which could be potential biomarkers in cervical cancer (Audirac-Chalifour et al., 2016). Specific bacteria might induce Th2 immunity through the RORγτ+Treg cells, IL-10, and Th17 cells in the cervical epithelium (Punt et al., 2015). The activities of these substances induced an abnormal state in the epithelial cells which promoted the incidence of cervical cancer (Bermudez-Morales et al., 2008; Punt et al., 2015).
Cancer immunotherapy has become increasingly sophisticated, especially cancer vaccines that stimulate the active immune system to target the tumor neo-antigens, which are unique to each patient’s tumor, and to facilitate recognition and elimination of transformed cells by the immune system (Fioretti et al., 2014; Mannan, 2016; Hobernik and Bros, 2018; Pandey et al., 2019; Shukla et al., 2020). For example, the creation of the HPV vaccine is well known for the prevention of cervical cancer. For the vaccines using recombinant DNA technology to prevent HPV infection, there are three types at present, including a bivalent vaccine against HPV16 and HPV18 (Cervarix), a tetravalent vaccine against HPV6, 11, 16, and 18 (Gardasil), and a nonavalent vaccine against HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 (Gardasil 9) (Garbuglia et al., 2020). The immunotherapy of breast cancer has been explored, including the use of targeted antibodies such as trastuzumab and pertuzumab. However, these antibodies are effective approaches only for patients whose tumors overexpress the human epidermal growth factor receptor 2 (HER2) antigen. For those patients without the HER2 antigen, these antibodies might not be useful (Coussens and Werb, 2002; Combadiere and Mahe, 2008; Mittendorf et al., 2011; Berger and Wunderink, 2013; Mattheolabakis et al., 2016). Therefore, a vaccine for breast cancer has been explored as an alternative to support the unmet needs of such patients, such as a particulate vaccine delivered via the skin, which was found to be a better route of immunization in a murine model (Weitzman and Gordon, 1990).The vaccines mentioned above were shown to be effective in cancer immunotherapy. Therefore, new cancer vaccines would greatly progress the treatment of cancer (Mattheolabakis et al.; Mittendorf et al.; Coussens and Werb, 2002; Combadiere and Mahe, 2008; Berger and Wunderink, 2013; Chablani et al., 2019; Garbuglia et al., 2020).
DNA Damage
Genetic changes, mainly those associated with DNA damage and repair, are known to be linked to cancer. If the DNA damage induced by microbes is not appropriately repaired, this might lead to mutations and genomic instability, eventually leading to cancer (De Bont and van Larebeke, 2004; Trabulus et al., 2012; Kidane et al., 2014). All of the following cancers involved DNA damage including CRC, ovarian cancer, HCC, gastric cancer, and lung cancer (Nalbandian et al., 2009; Shanmughapriya et al., 2012; Konstantinopoulos and Matulonis, 2018; Junaid et al., 2019b; Martin et al., 2019).
The enrichment of bacterial families in the CRC microbes is shown to produce genotoxins inducing damage in the host cell DNA, which might possibly lead to colorectal cancer. Martin et al. discovered that infection with Salmonella enterica, a genotoxin-producing bacterium, could enhance genomic instability both in two-dimensional and organotypic three-dimensional tissue models in FAP and the majority of sporadic CRC (Fearon, 2010). The APC gene might be lost after exposure to the genotoxic bacteria. The deficiency in APC is associated with the sustained activation of the DNA damage response and the reduced capacity to repair different types of damage, including DNA breaks and oxidative damages. Infection with genotoxic Salmonella was shown to prevent cell cycle arrest in APC-deficient cells (Martin et al., 2019). The cytolethal distending toxin produced by Escherichia and Campylobacter spp. could induce double-strand DNA break via its deoxyribonuclease activity to develop cancer (Cuevas-Ramos et al., 2010; He et al., 2019). Colibactin produced by members of the Enterobacteriaceae family could also induce DNA strand break (Buc et al., 2013). B. fragilis toxin (Goodwin et al., 2011) and ROS produced by E. Faecalis were both associated with DNA damage and genomic instability in vitro (Huycke, 2002; Wang and Huycke, 2007).
In ovarian cancer, Chlamydia were found to exist in tumor tissues, which might contribute to cancer through inhibiting apoptosis, inducing the DNA damage response and increasing the susceptibility to other infections (Shanmughapriya et al., 2012). Like Chlamydia, microbes might disrupt genetic stability to increase the incidence of ovarian cancer (Kidane et al., 2014). Large-scale genomic studies have shown that gene members of the homologous recombination repair pathway might have frequent genetic and epigenetic alterations in ovarian cancer. The deficiency in homologous recombination repair was shown to induce genomic instability and a hyper-dependence on alternative DNA repair mechanisms and to enhance the sensitivity of double-strand break-inducing agents (Konstantinopoulos and Matulonis, 2018).
As far as we know, H. pylori is related to HCC and gastric cancer. The cytotoxin-associated gene (Cag) pathogenicity island, which encodes a type IV secretion system that injects CagA into epithelial cells, is well known among the H. pylori virulence factors (Censini et al., 1996; Odenbreit, 2000; Asahi et al., 2000; Stein et al., 2000; Lai et al., 2006; Moore et al., 2011). The N-terminus of CagA could interreact with the tumor-suppressing protein and apoptosis-stimulating protein of p53 to subsequently disrupt the apoptotic function of the p53 tumor suppressor gene, which meant the possibility of progression to cancer was enhanced (Junaid et al., 2019).
Regional tumor peptides and even radiotherapy might lead to a microenvironment deregulation in granulomas, allowing the consequent proliferation of M. tuberculosis (Christopoulos et al., 2014). Chronic M. tuberculosis infection in a mouse model also induced squamous cells to aggregate in the lung, with malignancy and tumorigenicity possibly due to the DNA damage. The accumulation of DNA damage would be malignant and ultimately lead to lung cancer (Nalbandian et al., 2009).
Metabolism
Tumor cells must increase the import of nutrients from their environment to maintain a high metabolic level, due to their rapid growth compared with normal or quiescent cells, by adapting their metabolism to be more dependent upon aerobic glycolysis and glutaminolysis (Kidane et al., 2014; Deberardinis and Chandel, 2016; Weyandt et al., 2017). Warburg effect is the switched metabolism existing in cancerous cells, which primarily undergo aerobic glycolysis instead of oxidative metabolism. The tumor cells express increased glucose uptake and elevated lactate production different from the normal metabolism. Butyrate is the primary energy source of normal colonocytes, which could accumulate and inhibit the proliferation of cancerous colonocytes when the Warburg effect happens. Cancer cell metabolism could drive the divergence of epigenomic and transcriptome profiles in cancer cells away from their original cells and promote tumor development (Racker, 1972; Vander et al., 2009; Donohoe et al., 2012). The metabolic reprogramming of tumor cells including altering bioenergetics, enhancing biosynthesis, and redoxing balance improve cell fitness and provide a selective advantage during tumorigenesis (Deberardinis and Chandel, 2016). These activities enhance or suppress in tumor cells compared with normal metabolism which has a stable anabolic program (Deberardinis and Chandel, 2016). The tumor cells have various mechanisms to maintain the viability in nutrient- and oxygen-poor environments, such as decreasing their demand for ATP or stimulating ATP production by activating adenylate kinase (Strohecker and White, 2014; Deberardinis and Chandel, 2016). For microorganisms, all of them must regulate the uptake of nutrients and coordinate the metabolism of carbon, energy, and nitrogen (Chubukov et al., 2014). The normal microbe-derived metabolites containing SCFAs (particularly acetate, propionate, and butyrate) have the robust capacity to dampen intestinal inflammation, protect against pathogen invasion and maintain barrier integrity. Once this process is disrupted, the abnormal metabolism might affect the tumor growth (Zhang et al., 2019a). The metabolic substances, which helps cells acquire the energy that they need for growth, proliferation, and the maintenance of critical cellular processes, can support the biological processes that enable tumor growth (Vander Heiden and DeBerardinis, 2017; Weyandt et al., 2017). In addition, many microbes can produce toxins, specifically those that disrupt cellular signaling, to disturb the regulation of cell growth (Wei et al., 2012). As the metabolic profiles of tumor cells distinguishes them from normal cells and are responsible for their growth and survival, the metabolism would be innovative targets for the management and prevention of cancers (Weyandt et al., 2017).
In lung cancer patients, Ke et al. discovered that the metabolic characteristics of microbes were different in diverse sampling sites. Microbes in the tumors exhibited metabolic behaviors; antimicrobial resistance, protein folding, sorting and degradation, glycan biosynthesis and metabolism, metabolism of cofactors and vitamins and nucleotide metabolism were found to be enriched only in cancer patients (Wang et al., 2019). For example, airway microbes were observed to upregulate the phosphoinositide 3-kinase pathway, involved in the incidence of lung cancer, to participate in regulating cell proliferation, survival, and differentiation (Mendoza et al., 2011; Tsay et al., 2018). Thermus and Legionella were speculated to play a potential role in tumor progression, partially through different metabolic-related functions, such as reduced signal transduction, increased excretory systems, amino acid metabolism, aldosterone-regulated sodium reabsorption, or amoebiasis pathways (Gomes et al., 2019).
H. pylori has been shown to significantly increase the risk of gastric cancer (Tan and Wong, 2011; Kalaf et al., 2013; Chen et al., 2014). Guo et al. concluded H. pylori infection might reduce the expression of the AU-rich element RNA-binding factor 1 via the CagA/p-ERK/AUF1 pathway to promote the incidence of gastric cancer (Guo Y. et al., 2020). Xiaosun, et al. revealed the differences in metabolism among tumoral, peritumoral, and normal tissues. The nucleotide transport and metabolism, amino acid transport and metabolism and the inorganic ion transport and metabolism were significantly more abundant in the tumoral microbes, which were relevant to gastric cancer (Liu et al., 2018).
H. pylori might induce the incidence of HCC through not only the immune pathway but also metabolic-related way. Ki et al. postulated that H. pylori infection might promote the TGF-β1-dependent oncogenic pathway to disturb the balance between hepatocyte apoptosis and proliferation in a murine model of CCl4-induced fibrosis (Ki et al., 2010; Garcia et al., 2013; Okushin et al., 2018). After the intestinal barrier is damaged, the gut microbes might putatively flow into the portal vein to settle into the liver (Okushin et al., 2018). Subsequently, these microbes might cause HCC through multiple mechanisms, including the release of cancer-promoting and senescence-promoting metabolites, such as deoxycholic acid from the dysbiotic microbes, and an increased hepatic exposure to gut-derived microbiota-associated molecular patterns, such as lipopolysaccharide. The above conditions might promote hepatic inflammation, fibrosis, proliferation, and the activation of anti-apoptotic signals in turn (Yu and Schwabe, 2017). HCC might be prevented from manipulating the gut microbes by diet, lifestyle, antibiotics and probiotics, due to the abovementioned pathogenic mechanisms (Mima et al., 2017).
In ovarian cancer, it was found 46 different Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the bacteria of ovaries between cancer and control groups. The changeable metabolic characteristics in the tumors included increased pathways related to streptomycin biosynthesis, carbon fixation in photosynthetic organisms, glycosphingolipid biosynthesis-globo series, cyanoamino acid metabolism, glycerophospholipid metabolism, butirosin and neomycin biosynthesis, other glycan degradation, and so on. As for the decreased pathways in cancer tissue, the bacteria showed the reduced alpha-linolenic acid metabolism, biosynthesis of unsaturated fatty acids, sulfur metabolism, biotin metabolism, protein kinase activity, biosynthesis of ubiquinone and other terpenoid-quinones, two-component system, folate biosynthesis, cell motility and secretion, citrate cycle, and ribosome biogenesis in eukaryotes. These enrichments and reductions of pathways might be the consequence of the microbial effect, which were involved in the development of cancer (Li, 2020).
Lafuente Ibáñez de Mendoza et al. concluded that Porphyromonas gingivalis might play an important role in OSCC. The overexpressed defensins in the OSCC samples, which contained human neutrophil peptide-2 and human α-defensin, might promote the overexpression of nuclear factor kappa-light-chain-enhancer of activated B cells and the activation of cyclin-D1, an epidermal growth factor receptor ligand that promoted the growth of tumors, eventually provoking nuclear translocation. The possible mechanisms include epithelial mesenchymal transformation in malignant cells, tumor proliferation, and tumor invasion. However, the accuracy of this finding is still waiting to be confirmed in in vitro studies and animal models (Hoppe et al., 2016; Lafuente Ibanez de Mendoza et al., 2019).
Synergistic Pathogenesis
Although the pathogenic mechanisms of microbes in cancer can be divided into the four main areas of modulating inflammation, immunity, DNA damage, and metabolism, microbes can induce the incidence of cancer through multiple pathogenic mechanisms. In other words, the abovementioned pathogenic mechanisms may not work absolutely independent of each other (Francescone et al. 2011; Bouvard et al., 2009; Kidane et al., 2014; Weyandt et al., 2017). One type of cancer might occur due to two or more of these microbial mechanisms, as suggested in the following studies. The different pathogenic mechanisms might overlap in a single cancer.
The metabolic substances released by microbes can induce inflammatory, immune, genetic, and metabolic responses. It has been estimated that over 25% of human cancers are related to a chronic inflammatory status, which might be a consequence of microbial infection and immunologic abnormality (Bouvard et al., 2009). The stressed or dying cells due to microbial infection recruit different types of immune cells including macrophages, neutrophils, T-cells, and B-cells to promote inflammation further to activate various tumor-promoting inflammatory cytokines (Kuraishy et al., 2011). Chronic inflammation could produce an immunosuppressive microenvironment to support tumor development and inhibit anti-tumor immunity (Shalapour and Karin, 2019). In prostate cancer, Mycoplasma hyorhinis might induce tumorigenesis not only indirectly through a partial chronic inflammatory response, but also directly through bacterial protein products, such as p37, that exert oncogenic effects (Ketcham et al., 2005; Goodison et al., 2007). In lung cancer, microbes might lead to malignancy through microbial dysbiosis, genotoxicity and virulence effects, inflammation, immune responses, and metabolism (Weitzman and Gordon, 1990; Coussens and Werb, 2002; Ballaz and Mulshine, 2003; Roesler et al., 2012; Liu H. X. et al., 2018). After damaging the pulmonary epithelium, the cytokines, released by infiltrating lymphocytes and macrophages, might induce a cytokine cascade and a proliferation of the lung epithelial cells. Subsequently, the breaks in the chromosomal strands and the accumulation of DNA mutational changes might be eventually activated by ROS (Weitzman and Gordon, 1990; Ballaz and Mulshine, 2003).
The gut microbes, which are well known in the development of colorectal cancer, induce various physiological functions, including cell proliferation, angiogenesis and apoptosis (Dolara et al., 2002; Stappenbeck et al., 2002; Rakoff-Nahoum and Medzhitov, 2007; Cheesman et al., 2011). The intestinal microbes in some sub-groups of colorectal cancer patients contain more bacteria that could produce metabolites or genotoxins, such as cytolethal distending toxin and colibactin, to result in gastrointestinal tract inflammatory diseases or to affect the tumorigenesis of colorectal cancer. Some of them can be directly pro-carcinogenic or opportunistic microorganisms in the tumor-associated microenvironment. For example, The cytolethal distending toxin produced by Escherichia and Campylobacter spp. (Cuevas-Ramos et al., 2010; He et al., 2019), Colibactin produced by members of the Enterobacteriaceae family (Buc et al., 2013), B. fragilis toxin (Goodwin et al., 2011) and ROS produced by E. Faecalis could induce the DNA strand break which might be associated with tumorigenesis (Huycke, 2002; Wang and Huycke, 2007). E. coli containing the polyketide synthase (pks) genotoxic island induced the DNA damage in vitro and in vivo and developed CRC in azoxymethane-treated IL-10 deficient mice (2012). After the cocolonization with pks+ E. coli and Bacteroides fragilis, the DNA damage was obviously enhanced in the mice colon epithelial cells. The mucus degradation increased adhesion of pks + E. coli and induced DNA damage in colon epithelial cells. Bacteroides fragilis promoted the IL-17 induction with early augmentation by pks+ E. coli cocolonization (Dejea et. al., 2018).
The interaction between microbes and colon tissue might activate the pro-carcinogenic signaling pathways and result in molecular changes, ultimately leading to cancer (Wong and Yu, 2019; Zorron Cheng Tao Pu et al., 2019). Human CRC tumors expressed more chemokine (C-C motif) ligand 2/monocyte chemoattractant protein 1 (CCL2/MCP-1) than the healthy colon sites. Satu Pekkala et al. discovered that the exposure of CRC cells to bacterial flagellin increased interleukin 6 (IL6) and CCL2/MCP-1 mRNA expression and IL6 excretion. Flagellin was shown to decrease caspase-1 activity and the production of ROS to increase cytotoxicity in CRC cells. Conditioned media from flagellin-treated CRC cells deteriorated the C2C12-myotubes and decreased their numbers. Increased flagellated microbes might promote CRC survival by inducing inflammatory proteins, including MCP-1 and others (Pekkala et al., 2019). In animal studies, evidence has suggested that microbes can directly contribute to the development of CRC through interaction with the immune system, the production of cancer-associated metabolites and the release of genotoxic virulence factors (Arthur et al., 2012; Kostic et al., 2013; Zackular et al., 2013). The Bacteroides fragilis toxin might be a risk factor for developing CRC, which upregulated the spermine oxidase (SMOX) gene expression in human normal colon epithelial cells (Goodwin et al., 2011). The SMOX protein played an important role in the alteration of polyamine metabolism, which catalyzed the oxidation of spermine to spermidine and produced hydrogen peroxide and aldehydes to result in apoptosis, DNA damage, and consequently the development of CRC (Goodwin et al., 2011; Snezhkina et al., 2016). In a drosophila model of gut pathogenesis, the intestinal infection with Pseudomonas aeruginosa could activate the c-Jun N-terminal kinase (JNK) pathway as a homeostatic compensatory mechanism to replenish the apoptotic enterocytes. However, when Pseudomonas aeruginosa infected animals with a latent oncogenic form of the Ras1 oncogene, this homeostatic mechanism could lead to massive over-proliferation of intestinal cells (Apidianakis et al., 2009). The Imd–dTab2–dTak1 innate immune pathway was converged with Ras1V12 signaling on JNK pathway activation to induce the basal invasion and distant spread of drosophila’s posterior intestinal cells (Bangi et al., 2013). It means that bacterial infection could directly synergize with the genetic background to initiate stem cells-mediated tumorigenesis (Apidianakis et al., 2009; Bangi et al., 2013).
In addition to CRC, intestinal microbes have been involved in hepatic diseases due to the immunologic and metabolic communications between the liver and the intestine (Aykut et al., 2019). Yu et al. highlighted five potential key pathways that drove cancer-promoting liver inflammation, fibrosis, and genotoxicity, including leaky gut, microbe-associated molecular patterns (Toll-like receptor axis), dysbiosis, bacterial metabolites, and immunosuppression, which might synergize (Yu and Schwabe, 2017).
The tight connection between H. pylori and gastric cancer and the specific pathogenic mechanisms involving inflammation, immunity, and metabolism have been proposed (Goodwin, 1988). One well-known theory for the pathogenesis of H. pylori in gastric cancer is known as the leaking roof theory, which contains four potential steps that ultimately result in the barrier mechanism of the gastric mucosa being damaged. First, H. pylori penetrates the mucosal layer and settles on the surface of the gastric epithelial cells. Second, the bacteria releases toxic factors that damage the gastric epithelial cells. Third, various inflammatory cells and mediators appear. Fourth, the bacteria produce immunoreactive substances, in addition to others. The stepwise reaction might promote the gastric cancer (Goodwin, 1988). Further research is needed to confirm this theory. It was proposed that eradication of H. pylori infection could be used to prevent and cure gastric cancer (Tan and Wong, 2011; Lee Y. C. et al., 2016). In addition to H. pylori, lactic acid bacteria are thought to be associated with gastric cancer. Its pathogenic mechanism possibly includes the supply of exogenous lactate, which is a fuel source for cancer cells, promoting inflammation, angiogenesis, metastasis, epithelial-mesenchymal transition, immune evasion, production of ROS and N-nitroso compounds. Without the fuel, the survival rate of tumor cells would be greatly reduced. Lactic acid bacteria have anti-H. pylori properties that enable colonization by other non-H. pylori carcinogenic pathobionts (Vinasco et al., 2019).
To discover whether some other microbial mechanisms related to pancreatic cancer exist, besides changes in immune status (Pushalkar et al., 2018), Berk Aykut et al. observed that activation of the mannose-binding lectin–C3 cascade through the C3 complement pathway might cause inflammation induced by the oncogenic Kras, leading to fungal dysbiosis and promoting tumor progression. Inflammation might work as a consequence in metabolic progression, leading to cancer (Aykut et al., 2019).
Conclusions
From the abovementioned polysystemic cancers, we summarized the diversity and distinguishing quantities of microbes, especially bacteria, in normal and tumoral tissues in most types of malignant tumors, which helped us promote the idea of an existing relationship between cancer and microbes (Nilsson et al., 2006; Guo et al., 2012; Kostic et al., 2012; Garrett, 2015; Mitsuhashi et al., 2015; Audirac-Chalifour et al., 2016; Lee Y. C. et al., 2016; Liu H. X. et al., 2018; Okushin et al., 2018; Aykut et al., 2019; Haruki et al., 2019). Analyzing microbial changes could indicate the etiopathology of disease, help in the design of novel diagnostic and treatment strategies, supervise and manage disease progression, and predict cancer prognoses (Liu H. X. et al., 2018). Bacteria have so far remained as the most studied microbes worldwide, and bacteria might affect the incidence and development of cancer through four major special pathogenic mechanisms, including modulating inflammation, immunity, DNA damage, and metabolism.
However, the formation of some cancers is not limited to only one pathogenic mechanism. Different pathogenic mechanisms might overlap in one cancer to induce tumorigenesis (Bouvard et al., 2009; Francescone et al., 2014; Kidane et al., 2014; Weyandt et al., 2017). Many exact microbial-driven pathogenic mechanisms of cancers have not yet been discovered. It is not known whether the role of the microbes is the etiology or the consequence (Christopoulos et al., 2014; Banerjee et al., 2017; Cavarretta et al., 2017; Khoruts, 2018; Pandey et al., 2019).Though many studies have considered microbes as the etiology of cancers, we cannot deny the possibility that microbial changes are an effect of some cancers. The specific tumoral environment of low immunity might provide a specialized niche to help microbes colonize (Christopoulos et al., 2014; Banerjee et al., 2017; Cavarretta et al., 2017; Khoruts, 2018; Pandey et al., 2019). More studies should be performed to confirm the real role of microbes. If the etiologic role and the precise pathogenic mechanisms of microbes in different cancers are determined clearly, the early prevention and treatment of cancers will greatly progress with a higher efficiency and accuracy.
Author Contributions
QL, XF, and LH devised the conceptual idea. XF wrote the manuscript. LH, SM, LZ, LW, KZ, PY, LG, and WJ critically reviewed the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The authors wish to thank participating persons for their valuable input in the preparation of this manuscript at The First Affiliated Hospital of Xi’an Jiaotong University.
References
Al-Shabanah O. A., Hafez M. M., Hassan Z. K., Sayed-Ahmed M. M., Abozeed W. N., Al-Rejaie S. S., et al. (2013). Human papillomavirus genotyping and integration in ovarian cancer Saudi patients. Virol. J. 10 (1), 1–9. doi: 10.1186/1743-422X-10-343
Apidianakis Y., Pitsouli C., Perrimon N., Rahme L. (2009). Synergy between bacterial infection and genetic predisposition in intestinal dysplasia. Proc. Natl. Acad. Sci. 106 (49), 20883–20888. doi: 10.1073/pnas.0911797106
Ardies C. M. (2003). Inflammation as cause for scar cancers of the lung. Integr. Cancer Ther. 2 (3), 238–246. doi: 10.1177/1534735403256332
Arthur J. C., Perez-Chanona E., Muhlbauer M., Tomkovich S., Uronis J. M., Fan T. J., et al. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (6103), 120–123. doi: 10.1126/science.1224820
Asahi M., Azuma T., Ito S., Ito Y., Suto H., Nagai Y., et al. (2000). Helicobacter pylori Caga Protein Can Be Tyrosine Phosphorylated in Gastric Epithelial Cells. J. Exp. Med. 191 (4), 593–602. doi: 10.1084/jem.191.4.593
Audirac-Chalifour A., Torres-Poveda K., Bahena-Roman M., Tellez-Sosa J., Martinez-Barnetche J., Cortina-Ceballos B., et al. (2016). Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. PLoS One 11 (4), e0153274. doi: 10.1371/journal.pone.0153274
Aykut B., Pushalkar S., Chen R., Li Q., Abengozar R., Kim J. I., et al. (2019). The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574 (7777), 264–267. doi: 10.1038/s41586-019-1608-2
Ballaz S., Mulshine J. L. (2003). The potential contributions of chronic inflammation to lung carcinogenesis. Clin. Lung Cancer 5 (1), 46–62. doi: 10.3816/CLC.2003.n.021
Banerjee S., Tian T., Wei Z., Shih N., Feldman M. D., Alwine J. C., et al. (2017). The ovarian cancer oncobiome. Oncotarget 8 (22), 36225–36245. doi: 10.18632/oncotarget.16717
Bangi E., Pitsouli C., Rahme L. G., Cagan R., Apidianakis Y. (2013). Immune response to bacteria induces dissemination of Ras-activated Drosophila hindgut cells. Gut Microbes 13 (1), 569–576. doi: 10.1038/embor.2012.44
Berger G., Wunderink R. G. (2013). Lung microbiota: genuine or artifact? Isr. Med. Assoc. J. 15 (12), 731–733.
Bermudez-Morales V. H., Gutierrez L. X., Alcocer-Gonzalez J. M., Burguete A., Madrid-Marina V. (2008). Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest. 26 (10), 1037–1043. doi: 10.1080/07357900802112693
Bouvard V., Baan R., Straif K., Grosse Y., Cogliano V. (2009). A Review of Human Carcinogens—Part B: Biological Agents. Lancet Oncol. 10 (4), 321–322. doi: 10.1016/S1470-2045(09)70096-8
Brüssow H. (2020). Problems with the concept of gut microbiota dysbiosis. Microbial Biotechnol. 13 (2). doi: 10.1111/1751-7915.13479
Buc E., Dubois D., Sauvanet P., Raisch J., Delmas J., Darfeuille-Michaud A., et al. (2013). High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8 (2), e56964. doi: 10.1371/journal.pone.0056964
Caini S., Gandini S., Dudas M., Bremer V., Severi E., Gherasim A. (2014). Sexually transmitted infections and prostate cancer risk: A systematic review and meta-analysis. Cancer Epidemiol. 38 (4), 329–338. doi: 10.1016/j.canep.2014.06.002
Cameron S. J. S., Lewis K. E., Huws S. A., Hegarty M. J., Lewis P. D., Pachebat J. A., et al. (2017). A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One 12 (5), e0177062. doi: 10.1371/journal.pone.0177062
Castellarin M., Warren R. L., Freeman J. D., Dreolini L., Krzywinski M., Strauss J., et al. (2012). Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 22 (2), 299–306. doi: 10.1101/gr.126516.111
Cavarretta I., Ferrarese R., Cazzaniga W., Saita D., Luciano R., Ceresola E. R., et al. (2017). The Microbiome of the Prostate Tumor Microenvironment. Eur. Urol. 72 (4), 625–631. doi: 10.1016/j.eururo.2017.03.029
Censini S., Lange C., Xiang Z., Crabtree J. E., Ghiara P., Borodovsky M., et al. (1996). cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. U. S. A. 93 (25), 14648–14653. doi: 10.1073/pnas.93.25.14648
Chablani L., Tawde S. A., Akalkotkar A., D’Souza M. J. (2019). Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin. AAPS J. 21 (2):12. doi: 10.1208/s12248-018-0285-7
Chantziantoniou N., Donnelly A. D., Mukherjee M., Boon M. E., Austin R. M. (2017). Inception and Development of the Papanicolaou Stain Method. Acta Cytol. 61 (4-5), 266–280. doi: 10.1159/000457827
Cheesman S. E., Neal J. T., Mittge E., Seredick B. M., Guillemin K. (2011). Epithelial cell proliferation in the developing zebrafish intestine is regulated by the Wnt pathway and microbial signaling via Myd88. Proc. Natl. Acad. Sci. U. S. A. 108 Suppl 1, 4570–4577. doi: 10.1073/pnas.1000072107
Chen S., Duan G., Zhang R., Fan Q. (2014). Helicobacter pylori cytotoxin-associated gene A protein upregulates alpha-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer. Int. J. Oncol. 45 (2), 764–770. doi: 10.3892/ijo.2014.2444
Christopoulos A., Saif M. W., Sarris E. G., Syrigos K. N. (2014). Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin. Respir. J. 8 (4), 375–381. doi: 10.1111/crj.12094
Chubukov V., Gerosa L., Kochanowski K., Sauer U. (2014). Coordination of microbial metabolism. Nat. Rev. Microbiol. 12 (5), 327–340. doi: 10.1038/nrmicro3238
Clarke M. A., Rodriguez A. C., Gage J. C., Herrero R., Hildesheim A., Wacholder S., et al. (2012). A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect. Dis. 12:33. doi: 10.1186/1471-2334-12-33
Collaborators, U.S.B.o.D, Mokdad A. H., Ballestros K., Echko M., Glenn S., Olsen H. E., et al. (2018). The State of US Health 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA 319 (14), 1444–1472. doi: 10.1001/jama.2018.0158
Combadiere B., Mahe B. (2008). Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 31 (2-3), 293–315. doi: 10.1016/j.cimid.2007.07.015
Cong J., Zhang X. (2018). How human microbiome talks to health and disease. Eur. J. Clin. Microbiol. Infect. Dis. 37 (9), 1595–1601. doi: 10.1007/s10096-018-3263-1
Coussens L. M., Werb Z. (2002). Inflammation and cancer. Nature 420 (6917), 860–867. doi: 10.1038/nature01322
Cuevas-Ramos G., Petit C. R., Marcq I., Boury M., Oswald E., Nougayrède J. P. (2010). Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 107 (25), 11537–11542. doi: 10.1073/pnas.1001261107
De Bont R., van Larebeke N. (2004). Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19 (3), 169–185. doi: 10.1093/mutage/geh025
de Visser K. E., Eichten A., Coussens L. M. (2006). Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6 (1), 24–37. doi: 10.1038/nrc1782
Deberardinis R. J., Chandel N. S. (2016). Fundamentals of cancer metabolism. Sci. Adv. 2 (5), e1600200–e1600200. doi: 10.1126/sciadv.1600200
Dejea C. M., Fathi P., Craig J. M., Boleij A., Taddese R., Geis A. L., et al. (2018). Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359 (6375), 592–597. doi: 10.1126/science.aah3648
Dethlefsen L., McFall-Ngai M., Relman D. A. (2007). An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449 (7164), 811–818. doi: 10.1038/nature06245
Dickson R. P., Erb-Downward J. R., Huffnagle G. B. (2013). The Role of the Bacterial Microbiome in Lung Disease. Expert Rev. Respir. Med. 7 (3), 245–257. doi: 10.1586/ers.13.24
Dolara P., Caderni G., Salvadori M., Morozzi G., Fabiani R., Cresci A., et al. (2002). Fecal levels of short-chain fatty acids and bile acids as determinants of colonic mucosal cell proliferation in humans. Nutr. Cancer 42 (2), 186–190. doi: 10.1207/S15327914NC422_6
Donohoe D. R., Collins L. B., Wali A., Bigleroleij R., Sun W., Bultman S. J., et al. (2012). The Warburg Effect Dictates the Mechanism of Butyrate-Mediated Histone Acetylation and Cell Proliferation. Mol. Cell. 48 (4), 612–626. doi: 10.1016/j.molcel.2012.08.033
D’Souza M. J., Li R. C., Gannon M. L., Wentzien D. E. (2019). 1997-2017 Leading Causes of Death Information Due to Diabetes, Neoplasms, and Diseases of the Circulatory System, Issues Cautionary Weight-Related Lesson to the US Population at Large. IEEE Netw. 2019, 1–6. doi: 10.1109/ICESI.2019.8863033
Ertz-Archambault N., Keim P., Von Hoff D. (2017). Microbiome and pancreatic cancer: A comprehensive topic review of literature. World J. Gastroenterol. 23 (10), 1899–1908. doi: 10.3748/wjg.v23.i10.1899
Fan X., Alekseyenko A. V., Wu J., Peters B. A., Ahn J. (2018). Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67 (1), 120–127. doi: 10.1136/gutjnl-2016-312580
Fearon E. R. (2010). Molecular genetics of colorectal cancer. Ann. N. Y. Acad. Sci. 768 (1), 101–110. doi: 10.1146/annurev-pathol-011110-130235
Feng Y., Ramnarine V. R., Bell R., Volik S., Davicioni E., Hayes V. M., et al. (2019). Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics 20 (1), 146. doi: 10.1186/s12864-019-5457-z
Finegold S. M., Attebery H. R., Sutter V. L. (1974). Effect of diet on human fecal flora: comparison of Japanese and American diets. Am. J. Clin. Nutr. 12), 1456–1469. doi: 10.1093/ajcn/27.12.1456
Fioretti D., Iurescia S., Rinaldi M. (2014). Recent advances in design of immunogenic and effective naked DNA vaccines against cancer. Recent Pat. Anticancer Drug Discovery 9 (1), 66–82. doi: 10.2174/1574891x113089990037
Francescone R., Hou V., Grivennikov S. I. (2014). Microbiome, Inflammation, and Cancer. Cancer J. 20 (3), 181–189. doi: 10.1097/PPO.0000000000000048
Funda A. (2007). Detection of human papillomavirus DNA and genotyping in patients with epithelial ovarian carcinoma. J. Obstetr. Gynaecol. Res. 6 (33), 823–828. doi: 10.1111/j.1447-0756.2007.00663.x
Galdiero M. R., Bonavita E., Barajon I., Garlinda C., Mantovani A., Jaillon S., et al. (2013). Tumor associated macrophages and neutrophils in cancer. Immunobiol. Stuttgart. 218 (31), 1402–1410. doi: 10.1016/j.imbio.2013.06.003
Galdiero M. R., Marone G., Mantovani A. (2017). Cancer Inflammation and Cytokines. Cold Spring Harbor Perspect. Biol. a028662. doi: 10.1101/cshperspect.a028662
Garbuglia A. R., Lapa D., Sias C., Capobianchi M. R., Del Porto P. (2020). The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Front. Immunol. 11:188. doi: 10.3389/fimmu.2020.00188
Garcia A., Feng Y., Parry N. M., McCabe A., Mobley M. W., Lertpiriyapong K., et al. (2013). Helicobacter pylori infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis. Gut Microbes 4 (6), 577–590. doi: 10.4161/gmic.26042
Garrett W. S. (2015). Cancer and the microbiota. Science 348 (6230), 80–86. doi: 10.1126/science.aaa4972
Gillet E., Meys J. F., Verstraelen H., Bosire C., De Sutter P., Temmerman M., et al. (2011). Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect. Dis. 11, 10. doi: 10.1186/1471-2334-11-10
Gomes S., Cavadas B., Ferreira J. C., Marques P. I., Monteiro C., Sucena M., et al. (2019). Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma. Sci. Rep. 9 (1), 12838. doi: 10.1038/s41598-019-49195-w
Goodison S., Nakamura K., Iczkowski K. A., Anai S., Boehlein S. K., Rosser C. J. (2007). Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenet. Genome Res. 118 (2-4), 204–213. doi: 10.1159/000108302
Goodman B., Gardner H. (2018). The microbiome and cancer. J. Pathol. 244 (5), 667–676. doi: 10.1002/path.5047
Goodwin A. C., Shields C. E. D., Wu S., Huso D. L., Wu X. Q., Murray-Stewart T. R., et al. (2011). Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 108 (37), 15354–15359. doi: 10.1073/pnas.1010203108
Goodwin C. S. (1988). Duodenal ulcer, Campylobacter pylori, and the “leaking roof” concept. Lancet 2 (8626-8627), 1467–1469. doi: 10.1016/s0140-6736(88)90942-7
Gopalakrishnan V., Spencer C. N., Nezi L., Reuben A., Andrews M. C., Karpinets T. V., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359 (6371), 97–103. doi: 10.1126/science.aan4236
Goto T. (2020). Airway Microbiota as a Modulator of Lung Cancer. Int. J. Mol. Sci. 21 (9), 3044. doi: 10.3390/ijms21093044
Greathouse K. L., White J. R., Vargas A. J., Bliskovsky V. V., Beck J. A., von Muhlinen N., et al. (2018). Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 19 (1), 123. doi: 10.1186/s13059-018-1501-6
Grivennikov S. I., Greten F. R., Karin M. (2010). Immunity, Inflammation, and Cancer. Cell 140 (6), 0–899. doi: 10.1016/j.cell.2010.01.025
Guijon F., Paraskevas M., Rand F., Heywood E., Brunham R., McNicol P. (1992). Vaginal microbial flora as a cofactor in the pathogenesis of uterine cervical intraepithelial neoplasia. Int. J. Gynaecol. Obstet. 37 (3), 185–191. doi: 10.1016/0020-7292(92)90379-w
Guo Y. L., You K., Qiao J., Zhao Y. M., Geng L. (2012). Bacterial vaginosis is conducive to the persistence of HPV infection. Int. J. STD AIDS 23 (8), 581–584. doi: 10.1258/ijsa.2012.011342
Guo P., Tian Z., Kong X., Yang L., Shan X., Dong B., et al. (2020). FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2. J. Exp. Clin. Cancer Res. 39. doi: 10.1186/s13046-020-01677-w
Guo Y., Zhang T., Shi Y., Zhang J., Li M., Lu F., et al. (2020). Helicobacter pylori inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway. Helicobacter 25 (1), e12665. doi: 10.1111/hel.12665
Hanahan D., Weinberg R. A. (2000). The Hallmarks of Cancer. Cell 100 (1), 57–70. doi: 10.1016/S0092-8674(00)81683-9
Haruki K., Kosumi K., Hamada T., Twombly T. S., Vayrynen J. P., Kim S. A., et al. (2019). Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer. J. Pathol. 250 (4), 397–408. doi: 10.1002/path.5381
He Z., Gharaibeh R. Z., Newsome R. C., Pope J. L., Dougherty M. W., Tomkovich S., et al. (2019). Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin. Gut 68 (2), 289–. doi: 10.1136/gutjnl-2018-317200
Hobernik D., Bros M. (2018). DNA Vaccines—How Far From Clinical Use? Int. J. Mol. Sci. 19 (11), 3605. doi: 10.3390/ijms19113605
Holdeman L. V., Good I. J., Moore W. E. C. (1976). Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Appl. Environ. Microbiol. 31 (3), 359–375. doi: 10.1128/AEM.31.3.359-375.1976
Hoppe T., Kraus D., Novak N., Probstmeier R., Frentzen M., Wenghoefer M., et al. (2016). Oral pathogens change proliferation properties of oral tumor cells by affecting gene expression of human defensins. Tumour Biol. 37 (10), 13789–13798. doi: 10.1007/s13277-016-5281-x
Hosgood H. D. ,. 3., Sapkota A. R., Rothman N., Rohan T., Hu W., Xu J., et al. (2014). The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutagen 55 (8), 643–651. doi: 10.1002/em.21878
Hozumi M., Ogawa M., Sugimura T., Takeuchi T., Umezawa H. (1972). Inhibition of tumorigenesis in mouse skin by leupeptin, a protease inhibitor from Actinomycetes. Cancer Res. 32 (8), 1725–1728.
Hurtado C. G., Wan F., Housseau F., Sears C. L. (2018). Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer. Gastroenterology 155 (6), 1706–1715. doi: 10.1053/j.gastro.2018.08.056
Hussan H., Clinton S. K., Roberts K., Bailey M. T. (2017). Fusobacterium’s link to colorectal neoplasia sequenced: A systematic review and future insights. World J. Gastroenterol. 23 (48), 8626–8650. doi: 10.3748/wjg.v23.i48.8626
Huycke M. M. (2002). Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis 23 (3), 529–536. doi: 10.1093/carcin/23.3.529
Ito K., Yamaoka Y., Yoffe B., Graham D. Y. (2008). Disturbance of apoptosis and DNA synthesis by Helicobacter pylori infection of hepatocytes. Dig. Dis. Sci. 53 (9), 2532–2540. doi: 10.1007/s10620-007-0163-0
Jasemi S., Emaneini M., Fazeli M. S., Ahmadinejad Z., Nomanpour B., Sadeghpour Heravi F., et al. (2020). Toxigenic and non-toxigenic patterns I, II and III and biofilm-forming ability in Bacteroides fragilis strains isolated from patients diagnosed with colorectal cancer. Gut Pathogens. 12, 28. doi: 10.1186/s13099-020-00366-5
Jin J., Gan Y., Liu H., Wang Z., Li W. (2019). Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation. Lung Cancer 136, 129–135. doi: 10.1016/j.lungcan.2019.08.022
Johal H., Faedo M., Faltas J., Lau A., Mousina R., Cozzi P., et al. (2010). DNA of mouse mammary tumor virus-like virus is present in human tumors influenced by hormones. J. Med. Virol. 82 (6), 1044–1050. doi: 10.1002/jmv.21754
Junaid M., Shah M., Khan A., Li C. D., Khan M. T., Kaushik A. C., et al. (2019). Structural-dynamic insights into the H. pylori cytotoxin-associated gene A (CagA) and its abrogation to interact with the tumor suppressor protein ASPP2 using decoy peptides. J. Biomol. Struct. Dyn. 37 (15), 4035–4050. doi: 10.1080/07391102.2018.1537895
Kadhim H. S., Khuzaee L. R. M. A., Mahmood F. M. (2014). Detection of Human Papillomavirus-16 E6-Oncoprotein in Epithelial Ovarian Tumors Samples of Iraqi Patients. Jundishapur J. Microbiol. 7 (9), e11945–e11945. doi: 10.5812/jjm.11945
Kalaf E. A., Al-Khafaji Z. M., Yassen N. Y., Al-Abbudi F. A., Sadwen S. N. (2013). Study of the cytoxin-associated gene a (CagA gene) in Helicobacter pylori using gastric biopsies of Iraqi patients. Saudi J. Gastroenterol. 19 (2), 69–74. doi: 10.4103/1319-3767.108474
Karin M., Clevers H. (2016). Reparative inflammation takes charge of tissue regeneration. Nature 529 (7586), 307–315. doi: 10.1038/nature17039
Ketcham C. M., Anai S., Reutzel R., Sheng S., Schuster S. M., Brenes R. B., et al. (2005). p37 Induces tumor invasiveness. Mol. Cancer Ther. 4 (7), 1031–1038. doi: 10.1158/1535-7163.MCT-05-0040
Khoruts A. (2018). Targeting the microbiome: from probiotics to fecal microbiota transplantation. Genome Med. 10 (1), 80. doi: 10.1186/s13073-018-0592-8
Ki M. R., Goo M. J., Park J. K., Hong I. H., Ji A. R., Han S. Y., et al. (2010). Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor-beta1-induced inflammatory signaling. Lab. Invest. 90 (10), 1507–1516. doi: 10.1038/labinvest.2010.109
Kidane D., Chae W. J., Czochor J., Eckert K. A., Glazer P. M., Bothwell A. L. M., et al. (2014). Interplay between DNA repair and inflammation, and the link to cancer. Crit. Rev. Biochem. Mol. Biol. 49 (2), 116–139. doi: 10.3109/10409238.2013.875514
Kim N. (2019). Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism. J. Gastroenterol. Hepatol. 34 (8), 1287–1295. doi: 10.1111/jgh.14646
Klevorn L. E., Teague R. M. (2016). Adapting Cancer Immunotherapy Models for the Real World. Trends Immunol. 37 (6), 354–363. doi: 10.1016/j.it.2016.03.010
Konstantinopoulos P. A., Matulonis U. A. (2018). Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. Hematol. Oncol. Clin. North Am. 32 (6), 997–1010. doi: 10.1016/j.hoc.2018.07.006
Kostic A. D., Gevers D., Pedamallu C. S., Michaud M., Duke F., Earl A. M., et al. (2012). Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22 (2), 292–298. doi: 10.1101/gr.126573.111
Kostic A. D., Chun E., Robertson L., Glickman J. N., Gallini C. A., Michaud M., et al. (2013). Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2), 207–215. doi: 10.1016/j.chom.2013.07.007
Kuraishy A., Karin M., Grivennikov S. I. (2011). Tumor promotion via injury- and death-induced inflammation. Immunity 35 (4), 467–477. doi: 10.1016/j.immuni.2011.09.006
Kux K., Pitsouli C. (2014). Tissue communication in regenerative inflammatory signaling: lessons from the fly gut. Front. Cell. Infect. Microbiol. 4, 49. doi: 10.3389/fcimb.2014.00049
Lafuente Ibanez de Mendoza I., Maritxalar Mendia X., Garcia de la Fuente A. M., Quindos Andres G., Aguirre Urizar J. M. (2019). Role of Porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review. J. Periodontal. Res. 55 (1), 13–22. doi: 10.1111/jre.12691
Lai Y. P., Yang J. C., Lin T. Z., Lin J. T., Wang J. T. (2006). Helicobacter pylori Infection and CagA Protein Translocation in Human Primary Gastric Epithelial Cell Culture. Helicobacter 11 (5), 451–459. doi: 10.1111/j.1523-5378.2006.00438.x
Laroumagne S., Salinas-Pineda A., Hermant C., Murris M., Gourraud P. A., Do C., et al. (2011). [Incidence and characteristics of bronchial colonisation in patient with lung cancer: a retrospective study of 388 cases]. Rev. Mal. Respir. 28 (3), 328–335. doi: 10.1016/j.rmr.2010.05.020
Lax A. J., Thomas W. (2002). How bacteria could cause cancer: one step at a time. Trends Microbiol. 10 (6), 293–299. doi: 10.1016/S0966-842X(02)02360-0
Lee S. H., Sung J. Y., Yong D., Chun J., Kim S. Y., Song J. H., et al. (2016). Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 102, 89–95. doi: 10.1016/j.lungcan.2016.10.016
Lee Y. C., Chiang T. H., Chou C. K., Tu Y. K., Liao W. C., Wu M. S., et al. (2016). Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 150 (5), 1113–1124 e1115. doi: 10.1053/j.gastro.2016.01.028
Lehtinen M., Ault K. A., Lyytikainen E., Dillner J., Garland S. M., Ferris D. G., et al. (2011). Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sexually Transmitted Infect. 87 (5), 372–376. doi: 10.1136/sti.2010.044354
Li L., Li X., Zhong W., Yang M., Xu M., Sun Y., et al. (2019). Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apc(min/+) mice. EBioMedicine 48, 301–315. doi: 10.1016/j.ebiom.2019.09.021
Li Q. (2020). The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. J. Ovarian Res. 13 (1). doi: 10.1101/562975
Liu X., Shao L., Liu X., Ji F., Mei Y., Cheng Y., et al. (2018). Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine 40, 336–348. doi: 10.1016/j.ebiom.2018.12.034
Liu H. X., Tao L. L., Zhang J., Zhu Y. G., Zheng Y., Liu D., et al. (2018). Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int. J. Cancer 142 (4), 769–778. doi: 10.1002/ijc.31098
Liu Y., O’Brien J. L., Ajami N. J., Scheurer M. E., Amirian E. S., Armstrong G., et al. (2018). Lung tissue microbial profile in lung cancer is distinct from emphysema. Am. J. Cancer Res. 8 (9), 1775–1787.
Luan H., Wang X., Cai Z. (2019). Mass spectrometry-based metabolomics: Targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders. Mass Spectrom Rev. 38 (1), 22–33. doi: 10.1002/mas.21553
Mannan S. (2016). Cancer vaccine clinical trials. Immunotherapy 8 (11), 1263–1264. doi: 10.2217/imt-2016-0126
Mantovani B. A. (2001). Inflammation and cancer: back to Virchow? Lancet 357(9255), 539–545. doi: 10.1016/S0140-6736(00)04046-0
Mao Q., Jiang F., Yin R., Wang J., Xia W., Dong G., et al. (2018). Interplay between the lung microbiome and lung cancer. Cancer Lett. 415, 40–48. doi: 10.1016/j.canlet.2017.11.036
Martin O. C. B., Bergonzini A., D’Amico F., Chen P., Shay J. W., Dupuy J., et al. (2019). Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells. Cell Microbiol. 21 (12), e13099. doi: 10.1111/cmi.13099
Matsuda K., Tsuji H., Asahara T., Matsumoto K., Takada T., Nomoto K. (2009). Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl. Environ. Microbiol. 75 (7), 1961–1969. doi: 10.1128/AEM.01843-08
Mattheolabakis G., Lagoumintzis G., Panagi Z., Papadimitriou E., Partidos C. D., Avgoustakis K. (2016). Transcutaneous delivery of a nanoencapsulated antigen: Induction of immune responses. Int. J. Pharm. 385 (1–2), 187–193. doi: 10.1016/j.ijpharm.2009.10.033
McDermott R., Leach J., Overman L., Lonardi S., Lenz H. J., Morse M. A., et al. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182. doi: 10.1016/S1470-2045(17)30422-9
McLaughlin-Drubin M. E., Munger K. (2008). Viruses associated with human cancer. Biochim. Biophys. Acta 1782 (3), 127–150. doi: 10.1016/j.bbadis.2007.12.005
Mehta R. S., Nishihara R., Cao Y., Song M., Mima K., Qian Z. R., et al. (2017). Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by Fusobacterium nucleatum in Tumor Tissue. JAMA Oncol. 3 (7), 921–927. doi: 10.1001/jamaoncol.2016.6374
Mendoza M. C., Er E. E., Blenis J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36 (6), 320–328. doi: 10.1016/j.tibs.2011.03.006
Mima K., Nakagawa S., Sawayama H., Ishimoto T., Imai K., Iwatsuki M., et al. (2017). The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett. 402, 9–15. doi: 10.1016/j.canlet.2017.05.001
Mitsuhashi K., Nosho K., Sukawa Y., Matsunaga Y., Ito M., Kurihara H., et al. (2015). Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6 (9), 7209–7220. doi: 10.18632/oncotarget.3109
Mittendorf E. A., Alatrash G., Xiao H., Clifton G. T., Murray J. L., Peoples G. E. (2011). Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev. Vaccines 10, 6, 755–774. doi: 10.1586/erv.11.59
Miyake M., Ohnishi K., Hori S., Nakano A., Nakano R., Yano H., et al. (2019). Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. Cells 8 (3), 212. doi: 10.3390/cells8030212
Monney L., Sabatos C. A., Gaglia J. L., Ryu A., Waldner H., Chernova T., et al. (2002). Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415 (6871), 536. doi: 10.1038/415536a
Moore W. E. C., Holdeman L. V. (1974). Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl. Microbiol. 27 (5), 961–979. doi: 10.1128/AEM.27.5.961-979.1974
Moore W. E., Moore L. H. (1995). Intestinal floras of populations that have a high risk of colon cancer. Appl. Environ. Microbiol. 61 (9), 3202–3207. doi: 10.1128/AEM.61.9.3202-3207.1995
Moore M. E., Boren T., Solnick J. V. (2011). Life at the margins: modulation of attachment proteins in Helicobacter pylori. Gut Microbes 2 (1), 42–46. doi: 10.4161/gmic.2.1.14626
Nalbandian A., Yan B. S., Pichugin A., Bronson R. T., Kramnik I. (2009). Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 28 (17), 1928–1938. doi: 10.1038/onc.2009.32
Nelson W. G., De Marzo A. M., Isaacs W. B. (2003). Prostate cancer. New Engl. J. Med. 349 (4), 366. doi: 10.1056/NEJMra021562
Nilsson H. O., Stenram U., Ihse I., Wadstrom T. (2006). Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J. Gastroenterol. 12 (19), 3038–3043. doi: 10.3748/wjg.v12.i19.3038
Nosho K., Baba Y., Tanaka N., Shima K., Ogino S. (2010). Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 222 (4), 350–366. doi: 10.1002/path.2774
Odenbreit S. (2000). Translocation of Helicobacter pylori CagA into Gastric Epithelial Cells by Type IV Secretion. Science 287 (5457), 1497–1500. doi: 10.1126/science.287.5457.1497
Ogino S., Nosho K., Irahara N., Meyerhardt J. A., Baba Y., Shima K., et al. (2009). Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. Clin. Cancer Res. 15 (20), 6412–6420. doi: 10.1158/1078-0432.CCR-09-1438
Okushin K., Tsutsumi T., Ikeuchi K., Kado A., Enooku K., Fujinaga H., et al. (2018). Helicobacter pylori infection and liver diseases: Epidemiology and insights into pathogenesis. World J. Gastroenterol. 24 (32), 3617–3625. doi: 10.3748/wjg.v24.i32.3617
Pandey P., Bhatnagar A. K., Mohan A., Sachdeva K. S., Vajpayee M., Das B. K., et al. (2019). Insights in tuberculosis immunology: Role of NKT and T regulatory cells. Int. J. Mycobacteriol. 8 (4), 333–340. doi: 10.4103/ijmy.ijmy_141_19
Pandya D., Mariani M., Mchugh M., Andreoli M., Sieber S., He S., et al. (2014). Herpes Virus MicroRNA Expression and Significance in Serous Ovarian Cancer. PLoS One 9 (12), e114750. doi: 10.1371/journal.pone.0114750
Park H. E., Kim J. H., Cho N. Y., Lee H. S., Kang G. H. (2017). Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Archiv. 471 (3), 329–336. doi: 10.1007/s00428-017-2171-6
Pekkala S., Keskitalo A., Kettunen E., Lensu S., Nykanen N., Kuopio T., et al. (2019). Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota-A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia? Cancers (Basel) 11 (11), 1077. doi: 10.3390/cancers11111799
Perez-Losada M., Graham R. J., Coquillette M., Jafarey A., Castro-Nallar E., Aira M., et al. (2017). The temporal dynamics of the tracheal microbiome in tracheostomised patients with and without lower respiratory infections. PLoS One 12 (8), e0182520. doi: 10.1371/journal.pone.0182520
Punt S., van Vliet M. E., Spaans V. M., de Kroon C. D., Fleuren G. J., Gorter A., et al. (2015). FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma. Cancer Immunol. Immunother. 64 (6), 745–753. doi: 10.1007/s00262-015-1678-4
Pushalkar S., Hundeyin M., Daley D., Zambirinis C. P., Kurz E., Mishra A., et al. (2018). The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 8 (4), 403–416. doi: 10.1158/2159-8290.CD-17-1134
Quaranta V., Schmid M. C. (2019). Macrophage-Mediated Subversion of Anti-Tumour Immunity Cells (8) 7, 747. doi: 10.3390/cells8070747
Racker E. (1972). Bioenergetics and the Problem of Tumor Growth: An understanding of the mechanism of the generation and control of biological energy may shed light on the problem of tumor growth. Am. Sci. 60 (1), 56–63. doi: 10.1016/j.juro.2014.02.1209
Rakoff-Nahoum S., Medzhitov R. (2007). Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317 (5834), 124–127. doi: 10.1126/science.1140488
Repass J., Maherali N., Owen K. (2016). Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife 5, e10012. doi: 10.7554/eLife.10012
Repass J., Iorns E., Denis A. (2018). Replication Study: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife 7, e25801. doi: 10.7554/eLife.25801
Rizvi N. A., Hellmann M. D., Snyder A., Kvistborg P., Makarov V., Havel J. J., et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–28. doi: 10.1126/science.aaa1348
Roberti M. P., Picard M., Yonekura S. (2020). Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore? OncoImmunology 9, 1, 1778834. doi: 10.1080/2162402x.2020.1778834
Roesler B. M., Costa S. C., Zeitune J. M. (2012). Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterol. 2012:935410. doi: 10.5402/2012/935410
Ron S., Shai F., Ron M. (2016). Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 14 (8), e1002533–. doi: 10.1371/journal.pbio.1002533
Rooks M. G., Garrett W. S. (2016). Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16 (6), 341–352. doi: 10.1038/nri.2016.42
Routy B., Le Chatelier E., Derosa L., Duong C. P. M., Alou M. T., Daillere R., et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359 (6371), 91–97. doi: 10.1126/science.aan3706
Rubinstein M. R., Wang X., Liu W., Hao Y., Cai G., Han Y. W. (2013). Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14 (2), 195–206. doi: 10.1016/j.chom.2013.07.012
Ruffell B., Chang-Strachan D., Chan V., Rosenbusch A., Ho C. M., Pryer N., et al. (2014). Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (5), 623–637. doi: 10.1016/j.ccell.2014.09.006
Saito T., Nishikawa H., Wada H., Nagano Y., Sugiyama D., Atarashi K., et al (2016). Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22 (6), 679–684. doi: 10.1038/nm.4086
Samaranayake L., Matsubara V. H. (2017). Normal Oral Flora and the Oral Ecosystem. Dent. Clin. North Am. 61 (2), 199–215. doi: 10.1016/j.cden.2016.11.002
Shalapour S., Karin M. (2019). Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. Immunity 51 (1), 15–26. doi: 10.1016/j.immuni.2019.06.021
Shanmughapriya S., SenthilKumar G., Vinodhini K., Das B. C., Vasanthi N., Natarajaseenivasan K. (2012). Viral and bacterial aetiologies of epithelial ovarian cancer. Eur. J. Clin. Microbiol. Infect. Dis. 31 (9), 2311–2317. doi: 10.1007/s10096-012-1570-5
Shukla S., Wang C., Beiss V., Steinmetz N. F. (2020). Antibody Response against Cowpea Mosaic Viral Nanoparticles Improves In Situ Vaccine Efficacy in Ovarian Cancer. ACS Nano. 14 (3), 2994–3003. doi: 10.1021/acsnano.9b07865
Siegel R. L., Miller K. D., Jemal A. (2018). Cancer statistic. CA Cancer J. Clin. 68 (1), 7–30. doi: 10.3322/caac.21442
Snezhkina A. V., Krasnov G. S., Lipatova A. V., Sadritdinova A. F., Kardymon O. L., Fedorova M. S., et al. (2016). The Dysregulation of Polyamine Metabolism in Colorectal Cancer Is Associated with Overexpression of c-Myc and C/EBPβ rather than Enterotoxigenic Bacteroides fragilis Infection. Oxid. Med. Cell Longev. 2016, 1–11. doi: 10.1155/2016/2353560
So K. A., Yang E. J., Kim N. R., Hong S. R., Lee J. H., Hwang C. S., et al. (2020). Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection. PLoS One 15 (9), e0238705. doi: 10.1371/journal.pone.0238705
Sobhani I., Tap J., Roudot-Thoraval F., Roperch J. P., Letulle S., Langella P., et al. (2011). Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6 (1), e16393. doi: 10.1371/journal.pone.0016393
Sommariva M., Noci V. L., Bianchi F., Camelliti S., Sfondrini L. (2020). The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell. Mol. Life CMLS 77 (10), 2739–2749. doi: 10.1007/s00018-020-03452-8
Stappenbeck T. S., Hooper L. V., Gordon J. I. (2002). Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. U. S. A. 99 (24), 15451–15455. doi: 10.1073/pnas.202604299
Stavria P., Yiorgos A. (2013). Regenerative Inflammation: Lessons from Drosophila Intestinal Epithelium in Health and Disease. Pathogens 2 (2), 209–231. doi: 10.3390/pathogens2020209
Stein M., Rappuoli R., Cavacci A. (2000). Tyrosine phosphorylation of the Helicobacter pylori CagA .antigen after cag-driven host cell translocation. Proc. Natl. Acad. Sci. U. S. A. 97 (3), 1263–1268. doi: 10.1073/pnas.97.3.1263
Steinman R. M. (2012). Decisions About Dendritic Cells: Past, Present, and Future. Annu. Rev. Immunol. 30 (1), 1–22. doi: 10.1146/annurev-immunol-100311-102839
Strohecker A. M., White E. (2014). Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism. Autophagy 10 (2), 384–385. doi: 10.4161/auto.27320
Tan V. P., Wong B. C. (2011). Helicobacter pylori and gastritis: Untangling a complex relationship 27 years on. J. Gastroenterol. Hepatol. 26 Suppl 1, 42–45. doi: 10.1111/j.1440-1746.2010.06593.x
Tango C. N., Seo S. S., Kwon M., Lee D. O., Chang H. K., Kim M. K. (2020). Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development. Entific Rep. 10. doi: 10.1038/s41598-020-66607-4
Tappenden P., Harnan S., Ren S., Thokala P., Wong R., Mukuria C., et al. (2017). Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 35 (1), 97–109. doi: 10.1007/s40273-016-0440-x
Thiele Orberg E., Fan H., Tam A. J., Dejea C. M., Destefano Shields C. E., Wu S., et al. (2016). The Myeloid Immune Signature of Enterotoxigenic Bacteroides Fragilis-Induced Murine Colon Tumorigenesis. Mucosal Immunol. 10 (2), 421–433. doi: 10.1038/mi.2016.53
Tilg H., Adolph T. E., Gerner R. R., Moschen A. R. (2018). The Intestinal Microbiota in Colorectal Cancer. Cancer Cell 33 (6), 954–964. doi: 10.1016/j.ccell.2018.03.004
Torre L. A., Siegel R. L., Ward E. M., Jemal A. (2016). Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol. Biomarkers Prev. 25 (1), 16–27. doi: 10.1158/1055-9965.EPI-15-0578
Trabulus S., Guven G. S., Altiparmak M. R., Batar B., Tun O., Yalin A. S., et al. (2012). DNA repair XRCC1 Arg399Gln polymorphism is associated with the risk of development of end-stage renal disease. Mol. Biol. Rep. 39 (6), 6995–7001. doi: 10.1007/s11033-012-1529-8
Tsay J.-C. J., Wu B. G., Badri M. H., Clemente J. C., Shen N., Meyn P., et al. (2018). Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer. Am. J. Respiratory Crit. Care Med. 198 (9), rccm.201710–202118OC-. doi: 10.1164/rccm.201710-2118OC
Ubags N. D. J., Marsland B. J. (2017). Mechanistic insight into the function of the microbiome in lung diseases. Eur. Respir. J. 50 (3), 1602467. doi: 10.1183/13993003.02467-2016
Vander M., Lewis H., Craig C. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (N. Y. N. Y.) 234(5930), 1029–33. doi: 10.1126/science.1160809
Vander Heiden M. G., DeBerardinis R. J. (2017). Understanding the Intersections between Metabolism and Cancer Biology. Cell 168 (4), 657–669. doi: 10.1016/j.cell.2016.12.039
Vinasco K., Mitchell H. M., Kaakoush N. O., Castano-Rodriguez N. (2019). Microbial carcinogenesis: Lactic acid bacteria in gastric cancer. Biochim. Biophys. Acta Rev. Cancer 1872 (2), 188309. doi: 10.1016/j.bbcan.2019.07.004
Vriend H. J., Bogaards J. A., van Bergen J. E., Brink A. A., van den Broek I. V., Hoebe C. J., et al. (2015). Incidence and persistence of carcinogenic genital human papillomavirus infections in young women with or without Chlamydia trachomatis co-infection. Cancer Med. 4 (10), 1589–1598. doi: 10.1002/cam4.496
Wang X., Huycke M. M. (2007). Extracellular Superoxide Production by Enterococcus faecalis Promotes Chromosomal Instability in Mammalian Cells. Gastroenterology 132 (2), 551–561. doi: 10.1053/j.gastro.2006.11.040
Wang H., Funchain P., Bebek G., Altemus J., Zhang H., Niazi F., et al. (2017). Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Med. 9 (1), 14. doi: 10.1186/s13073-017-0405-5
Wang K., Huang Y., Zhang Z., Liao J., Ding Y., Fang X., et al. (2019). A Preliminary Study of Microbiota Diversity in Saliva and Bronchoalveolar Lavage Fluid from Patients with Primary Bronchogenic Carcinoma. Med. Sci. Monit. 25, 2819–2834. doi: 10.12659/MSM.915332
Watts D. H., Fazzari M., Minkoff H., Hillier S. L., Sha B., Glesby M., et al. (2005). Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J. Infect. Dis. 191 (7), 1129–1139. doi: 10.1086/427777
Wei J., Noto J., Zaika E., Romero-Gallo J., Correa P., El-Rifai W., et al. (2012). Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc. Natl. Acad. Sci. U. S. A. 109 (38), E2543–E2550. doi: 10.1073/pnas.1205664109
Weitzman S. A., Gordon L. I. (1990). Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76 (4), 655–663. doi: 10.1182/blood.V76.4.655.655
Weyandt J. D., Thompson C. B., Giaccia A. J., Rathmell W. K. (2017). Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am. Soc. Clin. Oncol. Educ. Book 37, 825–832. doi: 10.14694/EDBK_175561
Whisner C. M., Aktipis C. A. (2019). The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another’s Growth. Curr. Nutr. Rep. 8 (1), 42–51. doi: 10.1007/s13668-019-0257-2
Whitlock E. P., Williams S. B., Burda B. U., Feightner A., Beil T. (2015). in Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force (Rockville, MD: Agency for Healthcare Reseach and Quality(US)). Report No.:13-05193-EF-1.
Wolf A., Moissl-Eichinger C., Perras A., Koskinen K., Tomazic P. V., Thurnher D. (2017). The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study. Sci. Rep. 7 (1), 5867. doi: 10.1038/s41598-017-06361-2
Wong S. H., Yu J. (2019). Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat. Rev. Gastroenterol. Hepatol. 16 (11), 690–704. doi: 10.1038/s41575-019-0209-8
Xu N., Wang L., Li C., Ding C., Gu B. (2020). Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. Trans. Lung Cancer Res. 9 (4), 1554–1568. doi: 10.21037/tlcr-20-156
Yan X., Yang M., Liu J., Gao R., Hu S. (2015). Discovery and validation of potential bacterial biomarkers for lung cancer. Am. J. Cancer Res. 5 (10), 3111. doi: 10.4242/BalisageVol1.Marcoux01
Ye X., Wang R., Bhattacharya R., Boulbes D. R., Ellis L. M. (2017). Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors. Cancer Prev. Res. 10 (7), 398. doi: 10.1158/1940-6207.CAPR-16-0178
Yoon B. I., Kim S., Ha U. S., Sohn D. W., Cho Y. H. (2012). 42 Acute bacterial prostatitis: How to prevent and manage chronic infection? Eur. Urol. Suppl. 11 (1), e42. doi: 10.1016/S1569-9056(12)60041-4
Yu L. X., Schwabe R. F. (2017). The gut microbiome and liver cancer: mechanisms and clinical translation. Nat. Rev. Gastroenterol. Hepatol. 14 (9), 527–539. doi: 10.1038/nrgastro.2017.72
Yu G., Gail M. H., Consonni D., Carugno M., Humphrys M., Pesatori A. C., et al. (2016). Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol. 17 (1), 163. doi: 10.1186/s13059-016-1021-1
Zackular J. P., Baxter N. T., Iverson K. D., Sadler W. D., Petrosino J. F., Chen G. Y., et al. (2013). The Gut Microbiome Modulates Colon Tumorigenesis. Mbio 4 (6), e00692-13. doi: 10.1128/mBio.00692-13
Zanconato F., Cordenonsi M., Piccolo S. (2019). YAP and TAZ: a signalling hub of the tumour microenvironment. Nat. Rev. Cancer 19 (8), 454–464. doi: 10.1038/s41568-019-0168-y
Zhang Y., Fan X. G., Chen R., Xiao Z. Q., Feng X. P., Tian X. F., et al. (2005). Comparative proteome analysis of untreated and Helicobacter pylori-treated HepG2. World J. Gastroenterol. 11 (22), 3485–3489. doi: 10.3748/wjg.v11.i22.3485
Zhang Z., Tang H., Chen P., Xie H., Tao Y. (2019a). Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct. Targeted Ther. 4 (1), 41. doi: 10.1038/s41392-019-0074-5
Zhang Z., Zhao J., Tian C., Chen X., Li H., Wei X., et al. (2019b). Targeting the Gut Microbiota to Investigate the Mechanism of Lactulose in Negating the Effects of a High-Salt Diet on Hypertension. Mol. Nutr. Food Res. 63 (11), e1800941. doi: 10.1002/mnfr.201800941
Zhao H., Chu M., Huang Z., Yang X., Ran S., Hu B., et al. (2017). Variations in oral microbiota associated with oral cancer. Sci. Rep. 7 (1), 11773. doi: 10.1038/s41598-017-11779-9
Keywords: microbes, cancer, tumors, pathogenesis, relationships
Citation: Feng X, Han L, Ma S, Zhao L, Wang L, Zhang K, Yin P, Guo L, Jing W and Li Q (2020) Microbes in Tumoral In Situ Tissues and in Tumorigenesis. Front. Cell. Infect. Microbiol. 10:572570. doi: 10.3389/fcimb.2020.572570
Received: 17 June 2020; Accepted: 23 October 2020;
Published: 24 November 2020.
Edited by:
Nicolas Lapaque, INRA Centre Jouy-en-Josas, FranceReviewed by:
Yiorgos Apidianakis, University of Cyprus, CyprusCamille Martin-Gallausiaux, University of Luxembourg, Luxembourg
Copyright © 2020 Feng, Han, Ma, Zhao, Wang, Zhang, Yin, Guo, Jing and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qiling Li, liqiling@mail.xjtu.edu.cn